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Abstract
Taxol (paclitaxel) is one o f the most effective chemotherapeutic agents used for 
the treatment o f multiple cancers, including breast, ovarian, and, non-small-cell lung 
cancer. However, development o f taxol resistance with prolonged use is common, 
requiring the use o f  the chemotherapeutic agent in combination with other treatments. In 
addition to the development o f resistance, taxol is difficult to administer due to its high 
lipophilicity, and it requires solubilization with Cremophor EL (polyethoxylated castor 
oil) and ethanol, which often lead to adverse side-effects, including life-threatening 
anaphylaxis. Incorporation o f taxol in DPPC:DMPG (dimyristoyl phosphatidylcholine: 
dimyristoyl phosphatidylglycerol) liposomes may not only eliminate the adverse 
reactions associated with the Cremophor EL vehicle, but also decrease other toxicities 
that arise from the drug’s action in non-targeted tissues. Moreover, liposomally- 
encapsulated taxol might have the potential to overcome resistance by facilitating the 
cellular delivery o f  taxol at the site o f  action. Liposomes have been shown to be very 
effective in the delivery o f  other chemotherapeutic agents, such as adriamycin. This 
project deals with the use o f liposomes as a novel delivery method for taxol. The 
effectiveness o f  liposomally-encapsulated taxol, as well as its ability to overcome taxol- 
resistance, was tested on MCF-7 breast cancer cells and A549 lung cancer cells. It was 
also tested for its ability to overcome taxol-resistance in two taxol-resistant MCF-7 cell 
lines. The results o f  our studies demonstrated the following: i) the lipid components o f  
the liposomal formulation were non-toxic; ii) the liposomally-encapsulated taxol was 
more effective than conventional taxol in increasing the susceptibility o f  MCF-7 and 
taxol-resistant MCF-7 breast cancer cells as well as A549 lung cancer cells to taxol (as
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
determined by MTT cytotoxicity assays, DNA laddering, flow cytometry, and 
determination o f mitotic indexes); and, iii) the improved effectiveness o f  taxol delivered 
as a liposomal formulation was associated with higher intracellular levels o f the 
chemotherapeutic agent in cancer cells (determined by Ultra-Performance Liquid 
chromatographic technique). The results o f these studies indicate that liposomes may be 
potentially used as a novel method for the delivery o f  taxol in cancer chemotherapy.
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I. Introduction 
Chapter 1 : Chemotherapy and Paclitaxel
1.1 History o f  Paclitaxel:
The original form o f paclitaxel (taxol), derived from the Pacific yew tree {Taxus 
brevifolia), was discovered to exhibit marked anti-tumour activity against a variety o f  
rodent tumours during a biological screening program initiated by the National Cancer 
Institute (NCI) in the early 1960’s (Donehower, 1996). Although its biological activity 
was well-documented, little interest was shown in the compound until scientists at the 
Albert Einstein Medical College reported that it had a unique mode o f  action, at which 
point the NCI began clinical trials with paclitaxel in 1984 (Sengupta et al., 2001). 
However, isolation o f taxol from the Pacific yew tree, a non-renewable resource, 
involved a slow and low-yielding process. As a result, the supply o f  yew trees, as well as 
taxol was quickly depleted (Donehower, 1996). In 1985, a diterpenoid comprising the 
complex tetracyclic core o f paclitaxel called 10-deacetylbaccatin III (DAB) was isolated 
from the leaves o f  the European yew, which is a renewable resource. This discovery 
allowed the use o f  semisynthetic methods to secure a long-term supply o f  taxol (Miller et 
al., 2001). Because o f  the enormous cost o f  studying and manufacturing taxol, the NCI 
handed over the commercial rights to taxol to Bristol-Myers-Squibb (BMS) in 1989 
(Cragg, 1999).
In December o f  1992, the FDA approved taxol for the treatment o f  ovarian 
cancer, and in 1994 the drug was approved for the treatment o f breast cancer. The process 
from initial isolation o f the bark o f  the Pacific yew to the actual treatment o f patients took
8
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31 years. To date, taxol is the best-selling cancer drug ever manufactured, with its annual 
sales peaking in 2000 by reaching $1.6 billion (Miller et al., 2001).
1.2 Chemical nature o f  Taxol:
Taxol is a naturally-occurring poly-oxygenated diterpenoid with the chemical formula 
C4 7 H5 1N O 1 4 and a molecular weight o f 854.93 (Figure 1). Pure taxol is a white 
crystalline powder. It is insoluble in water, highly lipophilic, and it has a melting point o f 
217°C.
o
/ \ y \
Y  O"».
ÔH
P  OH
Figure 1: The chemical structure o f  the 
chemotherapeutic agent Taxol (Carmichael et 
al., 1987).____________________________________
1.3 Mechanism o f  Action:
While other classes o f  chemotherapeutic drugs directly target DNA via its 
replication and regulatory proteins, paclitaxel interferes with the dynamic instability o f  
microtubules. Specifically, it binds to the 13-tubulin subunit o f the tubulin protein that 
makes up microtubules to hyper-stabilize their structure (Figure 2). In normal cell
9
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growth, these microtubules would be broken down or destroyed once the cell stops 
dividing, which is a process necessary for regular cell function. The ability to 
depolymerize microtubules via the removal o f  tubulin subunits also grants the 
cytoskeleton the flexibility needed for cellular transport. Once this flexibility is lost, 
chromosome movement is disrupted during mitosis, preventing further cell division by 
blocking the cell cycle in M phase, specifically between prophase and anaphase (Miller et 
al., 2 0 0 1 ).
A. B.
+ end
Figure 2: A) A  microtubule cut away to show the interior surface. Paclitaxel binds 
along the interior surface o f  the microtubule, suppressing its dynamics (adapted from 
(Jordan et al., 2004). B. Microtubules in a bovine pulmonary artery endothelial cell 
visualized with fluorescently-labelled paclitaxel (Andreu, JM, et al. 2001).
Following tubulin binding and M phase block, the cell enters cell stress, which 
involves the activation o f  specific pathways in the cell including MAP kinase activation
10
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(Y. Huang et al., 1999). Under prolonged stress, the cell ultimately undergoes cell death 
or apoptosis (Figure 3). This mechanism affects both normal and cancerous cells, but 
since cancer cells are dividing at a much more rapid rate than non-cancerous cells, they 
are far more susceptible to paclitaxel-induced microtubule inhibition. Recent research has 
indicated that paclitaxel may also induce programmed cell death (apoptosis) in cancer 
cells by binding to an apoptosis stopping protein Bcl-2 (B-cell leukemia 2), thereby 
impeding its function (Michieli et al., 1999).
Figure 3: A. Untreated MCF-7 breast cancer cells show little signs o f apoptosis under 
brightfield microscopy. B. Cells incubated with paclitaxel are much larger in size, they 
are multi-nucleated due to hyper-polymerization o f microtubules, and many cells show 
signs o f  apoptosis (bright, round, floating, membrane blebbing).______________________
1.4 Pre-clinical Trials:
Prior to treatment o f  patients, any new drug must first pass a battery o f  tests 
examining its pharmacological activity and acute toxicity potential in humans. The 
overall goal o f  pre-clinical studies is to determine if  the new treatment is reasonably safe 
for use in humans, and if  it warrants further commercial development. Next, the creator
11
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or sponsor o f  the drug must file a new drug application and begin a process o f clinical 
trials that is both lengthy and expensive (Figure 4) (Hashida et ah, 2005).
1.5 Clinical Trials:
Clinical trials are ethically-approved research studies carried out in order to 
improve the health care o f  patients by determining if  promising approaches to cancer 
prevention, diagnosis, and treatment are safe and effective (National Cancer Institute, 
2006). There are several different types o f clinical trials, including trials for prevention, 
screening, diagnosis, treatment, and quality o f life. It is one o f the final stages o f the drug 
discovery research process, and these trials can typically be broken down into three 
phases: phase I, phase II and phase III (Wierenge et a l, 2007).
Phase I clinical trials involve a study on human subjects to determine how a new 
treatment should be administered, what dose should be given, and what side effects occur 
with increasing doses. These initial studies involve only a small number o f  subjects, and 
they may also determine the metabolism and pharmacologic actions o f  the treatment in 
humans. Phase I clinical trials for taxol began in 1984 and taxol was tested against a 
number o f  different cancer types (Cragg, 1999).
Phase II clinical trials are controlled clinical studies to determine the efficacy of 
the treatment for a particular indication. These studies are conducted with patients who 
have the disease in question, and they aim to determine any common side effects while 
continuing to test the safety o f the treatment. In 1988, the results o f Phase II trials testing 
taxol on ovarian cancer were extremely successful, which suggested the potential for the 
wide-spread use o f  the drug across the United States (Cragg, 1999).
12
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Phaselll clinical trials test a new treatment for a specific condition against the 
current standard treatment. These studies are only conducted if  phase I and phase II 
studies indicate that the new treatment will be effective and safe. They gather additional 
information about the overall benefits and risks o f the treatment, and they typically enroll 
a large number o f patients. Following phase III clinical trials, a new treatment can be 
used for the general population, but it will continually be monitored for safety and to 
determine optimal use (National Cancer Institute, 2006). In 1989, it was announced that 
phase III trials o f  taxol on ovarian cancer were successful, and in 1991, it was determined 
that taxol was also effective for treatment o f metastatic breast cancer (Cragg, 1999). 
Multiple phase III clinical trials are currently in progress testing taxol in combination 
with other chemotherapeutics and to determine its efficacy against different types of 
cancers.
13
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1.6 Chemotherapeutic use in clinic:
Taxol is most commonly used to treat ovarian, breast, non-small-cell lung cancer, and 
AIDS-related Kaposi’s sarcoma at a typical doses o f 175 mg/m^ (T. K. Yeh et al., 2005). 
Currently, clinical trials are being done to combine taxol with other anticancer drugs to 
treat many different types o f  cancer, such as lymphoma, and cancers o f the stomach, 
esophagus, bladder, prostate, uterus, cervix, head, and neck. Taxol is useful over other 
chemotherapy treatments because o f its unique method o f action. Since taxol does not 
directly target the genome, it is effective alone as first-line treatment or in combination 
with DNA-damaging drugs in tumours that do not respond to other chemotherapies 
(Trocketal., 1997).
14
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1.7 Current formulation o f  taxol:
Due to its low aqueous solubility (less than 0.03 mg/ml), paclitaxel is 
dissolved for clinical use in anhydrous ethanol and polyethoxylated castor oil 
(Chremophor EL) in a 1:1 (vohvol) ratio. It is then mixed in a saline solution for delivery 
to the patient in a 1:10 (vohvol) ratio, for a final concentration o f 0.3 to 0.6 mg/ml. The 
primary elimination pathways for the Cremophor EL (CrEL) formulation o f  taxol involve 
hepatic metabolism and biliary excretion (Kennedy et al, 2004). CrEL is not an inert 
vehicle, and it has been shown to exert a range o f  biological effects. Specifically, CrEL 
has been shown to cause toxic side effects, including acute anaphylaxis (Gelderblom et 
al, 2001). The dose-limiting toxicity o f taxol is neutropenia, which involves an abnormal 
decrease in the number o f neutrophils (the most common type o f  white blood cells) in the 
blood. This condition is directly related to the duration o f time that plasma taxol 
concentrations are at or above the threshold value (0.05 uM) (Kennedy et ah, 2004). 
Other side effects include myelotoxicity, peripheral neuropathy, decreased bone marrow 
function, blood problems, liver damage, severe nausea and diarrhea, alopecia, and joint or 
muscle pain (Sparreboom et ah, 2005; Trock et ah, 1997). Antihistamines and 
glucocorticoids are administered to manage these adverse side effects, but despite this 
premedication, minor hypersensitivity reactions have been found in 41-44% o f all 
patients, and major life-threatening reactions in 1.5-3% (Pakunlu et ah, 2003).
In addition, these co-administered drugs have raised the possibility o f additional 
pharmacokinetic and pharmacodynamic interactions with paclitaxel (Sparreboom et ah, 
1999). The CrEL vehicle also exerts a range o f effects on the biodistribution o f the drug, 
resulting in a nonlinear disposition (Sparreboom et ah, 1999; van Tellingen et ah, 1999;
15
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T. K. Yeh et a l, 2005). Arterial paclitaxel has been shown to bind to fixed arterial 
elements, resulting in localization o f the drug in proximity to the delivery source for 
some time after application. Such localization prevents efficient tumour targeting, thereby 
increasing the likelihood o f  side effects while decreasing efficacy (Giannakakou et al., 
2000).
1.8 Recent Developments:
Recently, several research groups have attempted to develop alternative 
formulations o f  taxol in an attempt to avoid many o f the problems associated with the 
Cremophor EL (CrEL) vehicle. ABI-007 (Abraxane) is a new formulation o f taxol that 
does not use a solvent, but binds taxol to human albumin for delivery (Sparreboom et al., 
2005). In a phase II study o f this albumin-stabilized nanoparticle, advanced breast cancer 
patients had fewer side effects and responded well to the drug (Albumin-bound paclitaxel 
improves response rate vs docetaxel in metastatic breast cancer, 2007). In addition, 
premedication with steroids or antihistamines is not necessary with Abraxane, but is 
commonly administered with conventional taxol treatments (Green et al., 2006).
16
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Chapter 2: Drug resistance
2.1 Models o f  drug resistance:
Current chemotherapy regimes involving paclitaxel (taxol) are not only limited by 
toxic side-effects, but also in part by the development o f  resistance, resulting in 
unnecessary and ineffective treatment and discomfort for the patient, as well as a waste o f  
resources. Chemotherapy resistance is an important component o f cancer mortality in 
current therapy regimes. There are two prevalent models o f  drug resistance: inherent 
(intrinsic) resistance, and drug-induced (acquired) resistance. Intrinsic resistance models 
predict an inherent resistance due to a change in gene expression, resulting in the 
activation o f gene repair, activation o f detoxifying systems, inhibition o f drug influx, 
activation o f drug efflux pumps, or blockage o f  apoptosis (Figure 5; Szakacs et al., 2006). 
In this model, the tumour shows no response to chemotherapy at the time o f initial 
treatment. Alternatively, in the acquired resistance model, the tumour develops resistance 
after an initial response to treatment due to selection for drug-resistant cells in the 
tumour. It is expected that there is extensive overlap between the mechanisms 
responsible for these two distinct mechanisms o f chemotherapy resistance (Morin, 2003).
17
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Figure 5: Cellular factors that cause drug resistance 
(Szakacs et al., 2006)._____________________________
The acquired resistance phenotype is termed multidrug resistance (MDR), and it 
can involve resistance to numerous chemotherapies, such as the anthracyclines 
(doxorubicin, daunorubicin), the vinca alkaloids (vincristine), epipodophyllotoxins 
(etoposide), and taxanes (taxol, taxotere) (Yeh, et al., 2003). In drug-induced 
chemotherapy resistance, a process o f successive rounds o f selection and clonal 
expansion o f  resistant cells that express genes and proteins integral to drug resistance is 
the common model. In contrast, in intrinsic models o f  resistance, a fraction o f  tumours 
may already express such proteins without the selective pressure o f chemotherapy 
treatment (Morin, 2003).
The principal molecules commonly implicated in either model o f chemotherapy
resistance include those involved in drug efflux, such as P-glycoprotein (M DRl)
(Kamazawa et al., 2002), those involved in the apoptotic pathways, including Bcl-2,
caspases, phosphatidylinositol 3’-kinase (PI-3) and downstream molecules (ex: ART),
genes involved in cell adhesion and cellular growth control, including peripheral myelin
18
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protein 22 (PMP22) and integrin B5, and genes involved in DNA repair, such as BRCAl 
(Lafarge et ah, 2001).
2.2 Mechanisms o f  Taxol resistance:
Resistance to taxol can be modulated and enhanced by the Cremophor vehicle, 
which may induce an increase in expression o f the P-glycoprotein (P-gp) efflux system 
by altering the disposition o f the drug in vivo (Bhalla, 2003; Chiu et al., 2005). Class IP - 
glycoproteins have been shown to prevent the entry o f paclitaxel across the blood-brain 
barrier, and to promote its excretion through the gut (Bhalla, 2003; Greiner et al., 1999) 
(Figure 6 ). This P-glycoprotein efflux pump is a member o f the ATP-binding cassette 
(ABC) family o f transporters, and it is encoded by the multi-drug resistance gene M DRl 
(Gottesman, et al., 2002; Nakagawa et al., 1992). The MDR phenotype is one o f the most 
widely accepted causes o f chemotherapy failure in cancer patients. O f the 49 ABC 
transporter genes identified, ABCBl (M DRl-P-gp) is one o f  the most well known, and it 
confers resistance to multiple chemotherapeutic agents by exporting taxol and other 
cytotoxic, hydrophobic drugs from inside the cell to the extracellular space (Kamazawa et 
al., 2002; Yeh et al., 2003). These ABC transporters regularly function to detoxify and 
protect the body from xenobiotics, and they are often highly expressed in important 
pharmacological barriers (Gottesman et al., 2002; Greiner et al., 1999).
Through the acquisition o f the MDR phenotype, it has been surmised that tumour 
cells actively reorganize their microenvironment to increase cell adhesion and drug 
resistance. Specifically, the tumour cells themselves may produce a favourable extra­
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cellular matrix (ECM) by conditioning the neighbouring stroma to induce the production 
o f proteins such as collagen VI and E-cadherin (Morin, 2003).
Gene expression profiling studies have shown MDRl and its family members to 
have a multiple-fold increase in expression levels in taxol-resistant cell lines (Sugimura et 
al., 2004; Trock et al., 1997; Villeneuve et al., 2006). These data support the role o f  ABC 
transporters in drug resistance, but they also indicate a much more complex system with 
no universal set o f  resistance genes.
Anticancer
Membrane
IN
Antimitotic
Activ i ty
. 'J
I
+ Pi
o
Efflux Pump
Figure 6 : A  possible mechanism o f resistance is modulated 
by the Chremophor vehicle through the P-glycoprotein (P-gp) 
efflux system, as class I P-glycoproteins have been shown to 
prevent the entry o f taxol across the blood-brain barrier, and to 
promote its excretion through the gut. The system is an efflux 
pump powered by ATP that removes hydrophobic drugs (modified 
from Miller et al., 2001).
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Another potential mechanism o f intrinsic paclitaxel resistance is the presence o f  
beta-tubulin point mutations in tumour genomic DNA. Such mutations may impair the 
ability o f  paclitaxel or GTP to bind to the tubulin, thereby conferring resistance to the 
drug (Massing et al., 2000; Michieli et al., 1999; Monzo et al., 1999; Theodoulou et al., 
2004). In addition to these, class III beta-tubulin (P-tubulin) over-expression may also 
play a key role in the development o f drug resistance (Ferlini et al., 2003; Mross et al., 
2004). In vitro studies o f  paclitaxel resistance have shown that overexpression o f  class III 
P-tubulin induces paclitaxel resistance by reducing the ability o f  paclitaxel to suppress 
microtubule dynamics (Kavanagh et al., 2005). Mutations in P-tubulin confer resistance 
to taxol by altering microtubule dynamics, and not by interfering with the binding o f 
taxol to microtubules (Bhalla, 2003). The different tubulin isotype classes vary in their 
paclitaxel binding affinities, and type III P-tubulin has been identified at higher 
concentrations in tumour cell lines that are resistant to paclitaxel. These increased pill- 
tubulin levels may be attributed to the expression o f oncogenic epidermal growth factor 
receptor (EGFR) family kinases (Montgomery et al., 2000).
Alternatively, Bel-2 phosphorylation is a known marker for mitotic arrest and can 
be induced by paclitaxel in cellular systems. It has also been shown to be the earliest 
detectable molecular event linking microtubule disruption to apoptosis (Moos et al., 
1998). In vitro studies have also shown that paclitaxel resistance can be introduced 
through the inducible expression o f the anti-apoptotic Bcl-2 family member, Bcl-xl via 
paclitaxel treatment. These results suggest a role for paclitaxel in the mediation o f the 
expression o f  this family o f proteins, resulting in resistance to the drug. Another study o f  
gene signatures o f  paclitaxel resistance found that taxol-resistant breast cancer cells were
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found to possess markedly higher levels Bcl-2 compared to a wild-type parental cell line 
(Villeneuve et al., 2006). Members o f  the Bcl-2 family, including Bcl-xl are also 
commonly overexpressed in primary tumour samples, and have primarily been associated 
with chemoresistance and shorter disease-free survival (Williams et al., 2005).
Whatever the mechanism, drug resistance conferred or modulated by CrEL can 
pose a great problem in patient care. With all o f the problems associated with the current 
vehicle, alternate pharmaeeutical strategies must be explored to achieve optimal 
chemotherapeutic results using taxol. Encapsulation o f chemotherapy agents into 
nanoparticles such as liposomes has proven to be an effective strategy with great 
potential to overcome resistance and alleviate some o f the toxic side effects associated 
with conventional therapies (Elofheinz, et al., 2005; Massing et al., 2000; Sengupta et al., 
2001; Theodoulou et al., 2004).
2.3 Measuring Drug resistance and apoptosis:
The technique often employed in studying acquired drug resistance involves 
identifying chemotherapy-resistant cellular models and conducting gene or protein 
expression assays comparing the resistant cells to their sensitive counterparts. More 
recent work has focused on the use o f  patient samples and microarray technology to 
determine global gene expression, and to monitor the change in expression as resistance 
forms with treatment (Lamendola et al., 2003; Lee et al., 2004).
Due to the fact that there are no proven predictors o f  a patient’s response to 
chemotherapy, all cancer patients selected for chemotherapy w ill receive the same 
treatment regime, regardless o f  their genetic background or any other individual factor.
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Individualized treatments are not currently used to treat patients based on their 
susceptibility or resistance to any particular drug. This can be attributed, in part, to the 
fact that no universally accepted guidelines for complete analytical or clinical validation 
o f anticancer resistance exist. As a result, differences in techniques such as tissue 
collection methodologies, molecular targets, apoptosis assays, or variations o f  protocols 
have limited the ability to compare various studies from different institutions. In addition, 
there is an absence o f  standardized criteria to score the immunohistochemistry staining 
for chemoresistant protein expression, leading to observer bias, and making it difficult to 
compare results between different researchers. These factors all limit the ability o f  
clinical trials to validate work done in vitro.
The World Health Organization (WHO) and more recent Response Evaluation 
Criteria in Solid Tumours (RECIST) criteria for clinical tumour response evaluation are 
simple to use and they are widely accepted as a measure o f the therapeutic effect of 
anticancer agents. They were designed to allow for international standardization o f the 
reporting o f  cancer treatment results, and they classify treatment outcomes into four 
categories based on measurements o f  tumour size over time. The response to therapy can 
be classified as a complete response, partial response, no change, or progressive disease 
(Padhani et al., 2000). These two sets o f guidelines are comparable, with the main 
difference being in the method o f measurement; the newer RECIST guidelines use 
unidimensional rather than bidimensional measurements o f  tumour diameter, meaning 
that RECIST criteria utilize the sum o f the longest diameters o f  tumours, rather than the 
bidmensional WHO method, which uses the product o f  the longest diameter and that 
perpendicular to it, summed over all tumors (Gehan et al., 2000; Park et al., 2003).
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However, the WHO and RECIST criteria do not provide specific instructions on 
the methodology o f performing tumour measurements, and as a result, discrepancies due 
to interobserver and intraobserver variability still exist in many cases, even when 
following the WHO and RECIST guidelines (Erasmus et ah, 2003). Such inconsistencies 
often arise from observer variations in the identification and position o f lesion 
boundaries, which can be difficult or nearly impossible to measure. In addition, 
measurement errors that estimate the size o f small lesions can often result in the 
misclassification o f tumour response. Furthermore, variations in examination technique 
between independent review panels can account for disagreements in tumour size, and 
ultimately, tumour classification (Padhani et al., 2000).
With phase I and II clinical trials often being performed on a small group o f  
patients, the outcome may be impacted by even the smallest differences in reported 
tumour size, making any inconsistencies particularly problematic. As a result, clinical 
response as determined by RECIST or WHO must be evaluated in combination with 
other clinical factors, such as time to progression, disease-free survival (DFS), and 
overall survival (OS) in order to determine an actual survival benefit for a particular 
therapeutic agent (Padhani et al., 2000). In addition, the biochemical measure o f  
anti tumour effect in patients can provide another method to confirm tumour 
measurements.
Molecular markers studied in the laboratory are more reflective o f biological 
response, which may be assessed before actual clinical response is detectable. However, 
much more work will be necessary to determine the actual predictive value o f biological 
response with respect to clinical benefit. Research groups have formed in order to create
24
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
guidelines for performing specific studies, such as the RITA-CEPA group, which has 
standardized the assessment o f cell proliferation studies using bromodeoxyuracil (BRDU) 
incorporation. Their guide includes organ-specific photo guides to define staining 
thresholds and intensities, as well as methods to analyze generated data, and their aim is 
to provide standardization in order to increase the value o f data obtained and the 
conclusions drawn (Nolte et al., 2005). For specific and specialized studies it may be 
possible to standardize protocols, but for many other techniques, there is a great variance 
in laboratory practise between various institutions.
2.4 Strategies to overcome resistance:
There are numerous methods that have been employed in an attempt to overcome 
drug resistance both in vitro and in the clinical setting. Many focus on the encapsulation 
o f chemotherapy drugs into liposomes, microspheres, or nanoparticles that would ideally 
escape the common mechanism o f resistance, namely the p-glycoprotein efflux pump. 
Alternatively, oligo-nucleotides that are antisense to resistance genes (ie: M D R l, Bcl2, 
etc), have been used in gene therapy in vitro in an attempt to block the function o f  these 
genes in the cell and overcome resistance (Pakunlu et al., 2003). Water-soluble co­
polymer prodrug administration has also been investigated as a potential mechanism to 
overcome resistance (Zou, et al., 2004). However, these methods have not all been 
employed in combination with taxol, leaving many avenues o f research for further study 
in increasing the effectiveness o f taxol in chemotherapy regimes.
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Chapter 3 ; Liposomes
3.1 Liposomes:
The word “liposome” comes from the Greek words “lipid,” meaning “fat”, and 
“soma,” meaning “body”. Liposomes are lyotropic liquid crystals, meaning that the 
ordering effeets o f  the lipids are induced by changing the concentration within a solvent. 
They form self-assembling vesicles with an inner aqueous compartment surrounded by a 
lipid bilayer o f  naturally-occurring phospholipids (Goyal et al., 2005). They have a low  
intrinsic toxicity, and they are non-immunogenic, biocompatible, and biodegradable. 
Both lipophilic and hydrophilic drug types can be incorporated into liposomes; lipophilic 
drugs can be integrated into the phospholipid bilayer, while hydrophilic drugs can be 
stored in the inner aqueous compartment. To deliver liposomes to the site o f action, the 
liposome’s phospholipid bilayer can fuse with other bilayers such as the cell membrane, 
thus delivering the contents. As a result, particles or drugs that would not normally be 
able to diffuse through the membrane can be indiscriminately delivered past this bilayer. 
Alternatively, if  liposomes are small enough in diameter, they may be taken up directly 
by the cell through endoeytosis (Figure 7; Hashimoto et al, 1992).
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Figure 7: Internalization o f fluorescently-tagged liposomes. A-Liposomes bound to 
tumor cell surface, B-after incubation for 10 minutes, C-after 30 minutes. (Adapted 
from Hashimoto et al., 1992).__________________________________________________
3.2 Structure and composition o f  liposomes:
The specific composition o f  liposomes can differ, as several possible formulations 
using various phospholipids or surfactants, in varying ratios, will be used to successfully 
incorporate taxol within them. The use o f naturally-occurring phospholipids is important 
for drug delivery in order to abrogate any immunogenic response within the body. The 
surfactants dimyristoyl-phosphatidyl-glycerol (DMPG), dimyristoyl-
pho sphadtidylcholine (DMPC), dipalmitoyl-pho sphatidylcholine (DPPC), and
disaturated-phosphatidylcholine (DSPC) can be produced synthetically, but are naturally- 
occurring (Figure 8 ; Bernsdorff et ah, 1999). They are the main components o f natural 
human lung surfactant, and DPPC accounts for 60-70% by weight in normal humans. 
Lung surfactants are a mixture o f  lipids and proteins that coat the inside o f  mammalian 
lungs. They function to reduce the work o f breathing by forming a monolayer at the 
alveolar air/water interface, making them capable o f  lowering surface tension to near zero 
values. These surfactants can be used in combination to determine an optimum 
formulation for the efficient encapsulation and retention o f paclitaxel for delivery to cells.
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Figure 8: The chemical structure o f  lipids used in this 
study. (Adapted from Bernsdorff et al., 1999).
Another feature o f  liposomes is their versatility. In addition to the numerous types o f  
potential lipid components, liposomes can be coated in a polyethylene glycol (PEG) 
layer, which is inert in the body, allowing the liposome to have a longer circulating time 
in the blood. Liposomes with this coating are referred to as “stealth liposomes,” as PEG 
aids in the circumvention o f  macrophages o f  the immune system that are found in the 
blood stream, which primarily occurs in the liver or spleen (Vyas, et al., 2006). 
Pegylation functions to create a large hydrodynamic volume, thereby increasing the 
molecular mass o f the peptides (Molineux, 2002). This increased volume helps to shield 
the proteins from proteolytic enzymes (Harris et al., 2003; Yowell et al., 2002). Further, 
specific vitamins, antigens, or antibodies can be attached to the phospholipid bilayer in 
order to target a specific tumour type (Goyal et al., 2005) (see below).
28
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5.5 Targeting lipsomes:
There are numerous methods utilized to target liposomes to a specific cell type, 
including noncovalent association o f cell specific antibodies, coating with heat 
aggregated immunoglobulins M (IgM), addition o f glycoproteins or glycolipids, or 
covalent attachment o f  poly and monoclonal antibodies to the liposomes, which are then 
called “immunoliposomes” (Goyal et al., 2005). These immunoliposomes are potent 
carriers that result in the acceleration o f  cellular uptake due to the recognition o f the 
antibody by the target cell (Hatakeyama et al., 2007). Immunoliposomes have been 
created to target multiple components o f cancer cells, including membrane type 1 matrix 
metalloproteinase (M Tl-M M P) (Atobe et al., 2007; Hatakeyama et al., 2007), surface- 
bound nucleosomes (Elbayoumi et al., 2007), and Bcl-2/Bcl-xl (Hussain, et al., 2006), 
among others.
3.4 The Enhanced Perm eability and Retention effect:
The endothelial wall o f  normal human blood vessels is typically encapsulated by 
endothelial cells that are bound together by tight junctions, which function to maintain 
structure and to stop any large particles in the blood from leaking out o f the vessel. 
Liposomes up to a diameter o f  400-600 nm are able to accumulate in tumour tissue in a 
passive yet selective fashion due to an increased “leakiness” o f  tumour vasculature 
(Hashida et al., 2005). This is known as the enhanced permeability and retention effect 
(EPR effect), and it is reinforced by the accelerated growth o f  blood vessels in tumours. 
As a result, cancerous tissues are more likely to take up liposomes, while healthy tissues 
with regular growth rates are less likely to do so. In addition to this enhanced
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permeability effect, the cells that make up tumours are often spaced further apart, 
allowing accumulation and retention o f liposomes in this intercellular space. Also, the 
lymphatic system that typically removes nanoparticles like liposomes from healthy 
tissues is often only marginally found in tumour tissues, which facilitates the retention o f  
liposomes in the targeted tumour tissue (Hofheinz et al., 2005).
3.5 Liposomal encapsulation o f  anticancer agents:
Encapsulation efficiency is determined by the composition o f the liposome, 
including the lipid content used and the particle size. Encapsulation efficiency must be 
balanced with substrate permeability to achieve a useful formulation for drug 
administration. In addition, the liposomes must be able to retain paclitaxel long enough to 
use them for effective clinical administration.
Encapsulation o f  anti-cancer drugs into liposomes has been shown to result in their 
accumulation to higher concentrations in the tumour interstitium than following 
conventional delivery, as the potentially troubling pharmacokinetics o f  the drug are 
replaced by the pharmacokinetics o f  the liposomes (Chiu et al., 2005). As a result, the 
level o f plasma clearance and the volume o f distribution are reduced. Overall, the 
therapeutic index o f  the drug is improved, while the side effects o f the drug can be 
reduced, or in some cases, eliminated (Duan et al., 2004; Tzafriri et al., 2005; Yeh et al., 
2005).
For example, liposomal doxorubicin has been shown to reduce the cardiotoxicity 
that is often associated with its conventional delivery method (Tzafriri et al., 2005). As a 
result, the lifetime cumulative dose potential for doxorubicin treatment is increased with
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the liposomal formulation. This is a limiting factor in the current conventional therapy 
(Theodoulou et al., 2004). Two formulations o f liposomal doxorubicin are currently used 
in clinic to treat patients. Caelyx® is used to treat Kaposi’s sarcoma, and advanced 
recurrent ovarian cancer, and Myocet® is used to treat advanced metastatic breast cancer 
(Mross et al., 2004). In addition to alleviating side effects, these liposomal formulations 
have been shown to result in a longer half-life o f the drug, and an increased therapeutic 
index (Colombo et al., 2007; Mross et al., 2004).
Similar results have been found with liposomal etoposide, where myelosuppression 
was inhibited while the maximum tolerated dose was increased (Soepenberg et al., 2004). 
Liposomal daunorubicin was found to be more toxic than the free drug against multi-drug 
resistant cells, suggesting that liposome encapsulation can partially protect the drug from 
the P-glycoprotein efflux system (Massing et al., 2000). These studies demonstrate great 
potential for effective therapy using liposomal encapsulation o f anticancer drugs.
3.6 Other liposomal treatments:
Liposomal drug delivery has proven to be a successful mode o f treatment in cancer 
therapy as well as in the delivery o f  other forms o f  therapy, such as treatment involving 
metal chelation, vaccine, enzyme and hormone replacements, diagnostic imaging, and the 
treatment o f  skin and eye diseases, among others (Goyal et al., 2005). Aside from cancer 
treatment, liposomes have had the most success in their use as a vehicle for antimicrobial 
and antiviral treatment (Goyal et al., 2005).
Several types o f  antimicrobial drugs have been incorporated into liposomes, 
including those used to treat mycobacterial infections, fungal infections, and
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mycobacterial infections. In order to be effective in the treatment o f  mycobacterial 
infections, drugs must be able to effectively penetrate the host macrophage, infect 
intracellular sites, and preferably have reduced toxicity with ample effect at low doses to 
allow prolonged therapy (Goyal et al., 2005). Futhermore, antibiotics are only effective 
against intracellular infections if  they can penetrate phagocytic cells. Liposomes provide 
a useful mode o f delivery because they are able to localize in the liver and spleen, where 
many pathogenic microorganisms reside, and they can increase intracellular targeting in 
these cells (Goyal et al., 2005).
Liposomes are also effective for delivery o f antiviral therapy due to their ability to 
deliver the encapsulated drug across the cell membranes to and this effectively 
concentrates them at the disease site (Sinico et al., 2005). Specifically, liposomes have 
been used to treat herpes, hepatitis C and HIV (Ferguson et a l, 2006; Pecheur et al., 
2007; Sinico et al., 2005). In addition to chemical drugs, liposomes have been used as a 
delivery method for oligonucleotide agents and small interfering RNAs (siRNAs) which 
can be used to induce expression o f certain proteins or knock-down gene expression in a 
sequence-specific manner (Hussain et al., 2006).
Liposomal delivery o f  gene therapy has been a popular avenue o f  investigation as 
liposomal encapsulation protects these agents from degradation by cellular enzymes 
(Ferguson et al., 2006; Schyth et al., 2007). In addition, liposomes allow transfection o f 
large-sized genetic material to the cell in comparison to the conventional use o f viral 
transfection methods. Furthermore, liposomes are a safer method o f delivery, as the risk 
o f the virus becoming replication-competent and infectious is always a possibility (Goyal 
et al., 2005). Liposomes have not widely been used in gene therapy as a viable
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alternative to viral vectors as of yet, but it represents an avenue of research that is 
currently under investigation for numerous applications.
3.7 Liposomal taxol:
Several attempts have been made to replace Cremophor EL as a vehicle for the 
delivery o f taxol by incorporating it into liposomes. However, due to the insoluble nature 
o f taxol, problems involving entrapment efficiency and stability are often encountered. 
One group encountered difficulties when attempting to achieve acceptable entrapment 
efficiencies (Ceruti et al., 2000). As a result, water-soluble prodrugs o f taxol were 
incorporated to increase the efficiency, yet no difference in cytotoxicity was detected 
between the liposomal and conventional taxol formulations. However, PEG-ylated 
liposomes were shown to increase plasma half-life (Ceruti et al., 2000; Crosasso et al., 
2000). Another group attempted to increase stability by introducing cationic lipids, 
which differ from the usual neutral or anionic compositions. This method increased 
stability, but was not tested for efficacy (Campbell et al., 2001). In one case, a phase I 
study o f a liposome-encapsulated taxol formulation was conducted, but the trial was 
discontinued, as the liposomal formulation showed no improvement over current taxanes 
in use (Soepenberg et al., 2004).
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II. Summary
Taxol is a powerful chemotherapeutic agent with a unique method o f action that is 
primarily used to treat breast, ovarian, and non-small-cell lung cancers. However, it is 
difficult to administer due to its high lipophilicity, and as a result, it is dissolved in 
Cremophor EL, which has been associated with multiple adverse side effects, including 
life-threatening anaphylaxis. In addition, this vehicle is known to modulate the common 
development o f  drug resistance with prolonged treatment.
Drug resistance can be acquired or intrinsic, and multiple pathways have been 
implicated in taxol resistance, including expression o f the protein membrane pump P- 
glycoprotein, phosphorylation o f the Bcl-2 family o f proteins, mutations in the B-tubulin 
subunit o f  microtubules, and overexpression o f  the class III B-tubulin subtype, among 
others. Many studies have been conducted in an attempt to better understand these 
pathways and to develop methods to overcome drug resistance.
Liposomes are composed o f naturally-occuring phospholipids that are self­
assembling with an inner aqueous compartment surrounded by an outer lipid membrane 
layer. Both lipophilic and hydrophilic drugs can be incorporated into liposomes for drug 
delivery. Due to enhanced permeability and retention (EPR) effect, liposomes are known 
to preferentially accumulate in tumour tissues, making them particularly suitable for 
delivery o f  chemotherapeutics. Current liposomal drugs, such as liposomal doxorubicin 
have been shown to improve the therapeutic index, while alleviating the toxic side effects 
o f the drug. Liposomal encapsulation o f taxol intends to assuage the common side 
effects associated with its use, while circumventing the development o f resistance to the 
drug.
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III. O bjectives
Objective 1: Develop and characterize a paclitaxel-resistant breast cancer cell 
line. The chemotherapeutic effectiveness o f paclitaxel will be evaluated in a breast 
cancer cell line (MCF-7) and two paclitaxel-resistant cell lines (clone and tax-resistant), 
which were established from the cancer cell line MCF-7 via successive selections o f  
surviving colonies after paclitaxel treatments. These cell lines will be characterized for 
expression o f  the P-glycoprotein efflux pump and used to determine whether delivery o f  
paclitaxel as a liposomal formulation escapes the efflux by this pump.
Objective 2: Develop and characterize formulations o f liposomal paclitaxel. The 
liposomal formulations will consist o f phosphatidylcholine (DMPC; DPPC; DSPC) and 
phosphatidylglycerol (DMPG). The choice o f  liposomal paclitaxel formulation that will 
be used in the subsequent experiments will be determined following characterization o f  
the liposomal formulations for size (by particle size analysis), encapsulation efficiency, 
and stability.
Objective 3; Evaluate and compare the in vitro chemotherapeutic effectiveness 
of paclitaxel delivered to cultured breast cancer cells as a liposomal or conventional 
formulation. Flow cytometric analysis o f the cell cycle will be used to compare the 
effectiveness o f  both the conventional and liposomal formulations o f  paclitaxel after 
treatment o f cell cultures, and to determine the type o f  cell death that follows. The MTT 
cytotoxicity assay, mitotic indexes and DNA laddering will be used to assess the extent 
o f cell iiqury. Ultra-performance liquid chromatography (UPLC) will be used to analyze 
the cellular uptake o f  taxol by cultured cells challenged with the different paclitaxel
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formulations and assess whether the extent o f injury is directly related to the intracellular 
concentration o f paclitaxel.
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V . M aterials and M ethods:
Part 1: Establishment o f a taxol-resistant MCF-7 clone
4.1 Propagation o f  cultured cell lines:
MCF-7 cells are epithelial adenocarcinoma cells derived from a pleural effusion 
metastasis from a primary tumour in the mammary gland o f  a 69-year-old female. They 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Hyclone) 
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 pg/ml penicillin, and 100 
pg/ml streptomycin in a 5% (v/v) CO2  atmosphere at 37°C. MCF-7 cells were obtained 
from the American Tissue Culture Collection (ATCC). These MCF-7 cells (termed 
“wild-type A ”) were used to create a taxol-resistant colony (termed “clone”). Normal 
MCF-7 cells (termed “wild-type B”) and a taxol-resistant cell line, (termed “tax- 
resistant”), were also generously donated for this study by Dr. A. Parissenti from the 
Northern Ontario School o f Medicine (East campus).
A549 cells are epithelial cells (donated by Dr. Marina Ulanova) initiated through 
explant culture o f  cancerous lung tissue from a 58-year-old Caucasian male. They were 
maintained in DMEM/Ham’s F12K medium (Hyclone) with L-glutamine and 
additionally supplemented and maintained as detailed above.
Human dermal fibroblast cells (HSF-55) are derived from human skin. They are 
not transformed, and therefore they have a limited lifespan. These cells were used to 
determine the effects and toxicity o f treatment with liposomes on non-cancerous tissue. 
They were maintained in similar culture conditions as the MCF-7 cells, as detailed above. 
HSF-55 cells were generously donated by Dr. M. Tassotto at the cancer research lab in
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the Thunder Bay Regional Health Sciences Center. A summary o f the cell lines used in 
this study is given in Table 1.
Table 1. A summary o f  cell lines used in this study
Cell line Type o f  cells Abbreviation Source
MCF-7 Breast cancer Wild-type A ATCC
MCF-7 Breast cancer Wild-type B Dr. A. Parissenti
MCF-7 (taxol-resistant) Breast cancer Clone Isolated for this study from 
wild-type A
MCF-7 (taxol-resistant) Breast cancer Tax-resistant Dr. A. Parissenti
A549 Lung cancer A549 Dr. M. Ulanova
HSF-55 Skin HSF-55 Dr. M. Tassotto
4.2 Treatment o f  Cells
Unless otherwise indicated, cell cultures were plated, left overnight to adhere, and 
additional media containing serial dilutions o f the treatment were added the following 
day. Cells in treatment were incubated in 5% (v/v) CO2  atmosphere at 37°C between 24 
hours and 7 days, depending on the assay. The taxol used for encapsulation into 
liposomes was pure taxol in powder form, and “conventional taxol” in the Cremophor 
vehicle was purchased from Bristol-Myers Squibb (BMS) and donated by the pharmacy 
in the Cancer Centre o f  the Thunder Bay Regional Health Science Centre.
4.3 Doubling time analysis:
For each cell line, twenty-thousand cells were plated in each well o f two 6-well 
dishes. Cells were allowed to adhere overnight. The next day, one well o f  each plate was 
trypsinized and the cells were counted five times using an automated cell counter
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(Beckman Coulter). The counts for the two wells were averaged. Every second day, two 
more wells were trypsinized and counted in a similar manner. The equation o f the 
trendline o f  best fit was determined using Excel, and doubling time was calculated from 
this equation using the following formula [equation (1)]:
(1): [LN(Time2/slope)/exponent] -  [LN(Time 1 /slope)/exponent],
Cell doubling times were used to characterize resistant cell lines and their parental 
counterparts, as well as to determine the length o f  cell cycles for treatment o f  the various 
cell lines with taxol.
4.4 Establishing an MCF-7 taxol-resistant cell line (clone):
MCF-7 cells were obtained from the American Tissue Culture Collection. Cells 
were split into three 150 mm plates at a concentration o f 2.1 x 10  ^ cells per plate and 
taxol was added to each plate for a final concentration o f either 1 pM, 7.5 pM or 15 pM. 
After four days, plates were rinsed with IX PBS to remove dead floating cells, and fresh 
medium was added with the same concentrations o f  taxol. Cells were rinsed with PBS 
and medium was replaced two times over the following 12 days, and after 16 consecutive 
days o f  taxol treatment, cells from the 1 pM and 7.5 pM plates were trypsinized and split 
into two 100 mm culture dishes, leaving two plates from each drug treatment group. (No 
living cells were left after 15 pM treatment). One plate from each treatment group was 
left in fresh medium without any taxol, and the other plates were treated with 0.1 pM 
taxol. Cells in 100 mm culture dishes were maintained once per week for approximately 
45 days, at which point distinct colonies were visible on the plates cultured in medium 
without drug. Twenty-four colonies were selected and moved into individual wells o f a
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12-well plate and allowed to adhere overnight. After 24 hours, colonies were trypsinized 
and split into two identical replicate plates to re-disperse the cells within the wells. Re­
dispersed cells were allowed to adhere overnight, at which point the replicate wells were 
treated with either 1 juM or 2 pM taxol to check for resistance. A summary o f this 
process is shown in Figure 9. Six clones with favourable growth characteristics under 
taxol treatment were selected to undergo a colonization assay.
(16 days in treatment)
Maintained for -4 5  days in treatment
Colonies selected and placed in 
individual dish
Cells checked for taxol-res is tance
Figure 9: Development o f  a taxol-resistant MCF-7 clone.
4.5 Colony formation assay:
To characterize and compare resistant clones isolated from successive taxol 
treatments, a colony formation assay was performed. This experiment was also used to
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determine if  cells treated with various doses o f taxol could eventually resume growth to 
form colonies or whether they were destined for apoptosis. Six colonies o f potentially 
taxol-resistant MCF-7 clone cells were plated in 6-well dishes and treated with serial 
dilutions o f  taxol for 2 cell cycles (as determined by doubling time analysis -  section 
4.3). These were compared to parental MCF-7 cells (wild-type A), as well as another 
MCF-7 cell line (wild-type B) and a taxol-resistant cell line (Tax-resistant). After 
treatment, the drug was removed and replaced with fresh medium for an additional 2 cell 
cycles. Cells were then trypsinized and plated in serial dilutions in another 6-well dish to 
observe colony formation (Figure 10). Medium was replaced 2 times per week for 1 
month until colonies had formed. Medium was then removed, and cells were rinsed twice 
with PBS and stained with Coomassie Blue dye. Colonies were viewed under phase 
contrast microscopy and Image J software was used to score the number o f colonies, 
which were defined as a group o f cells >25 cells.
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Taxol (uM)
2 cell cycles ~ 4 days 
Rem ove drug
^  2 cell cycles ~ 4 days
1:100
\ Z
Incubate -  count colony formation
Figure 10: Colonization assay protocol
4.6 Standardization o f  the MTT in vitro cytotoxicity assay:
The MTT cytotoxicity assay is a standard colorimetric assay that measures cell 
proliferation and is commonly used to determine toxic potential o f various agents (Z. 
Wang, Butt, Wang, & Liu, 2007). The tetrazole MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) is reduced to purple formazan crystals in the mitochondria 
by the enzyme mitochondrial dehydrogenase, and these crystals can be solubilized and 
analyzed for absorbance (Carmichael et ah, 1987). This assay is most sensitive when the 
cells are in log growth phase, and so optimal plating densities and incubation lengths 
must be determined prior to the cytotoxicity assays. Cells were seeded in lOOul 
media/well using a serial dilution o f  concentrations ranging from 250 to 35000 cells per 
well with eight replicate wells per dilution. The cells were allowed to adhere overnight,
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and an additional 50 pi o f  media was added to each well as to replicate the MTT 
protocol. Cells were incubated for 24 hours or 4 days, at which point 15pi MTT (5 
mg/ml) was added. The plate was incubated for an additional four hours, at which point 
the medium was removed, and formazan crystals were dissolved in 50 pi DMSO. The 
absorbance values were read on a microplate reader (Powerwave xs. Biotec) at two 
wavelengths, 570 nm and 650 nm. This standard curve was used to determine optimal 
seeding densities for MTT assays to obtain an absorbance between 0.7 and 1.25.
4.7 MTT in vitro cytotoxicity assay
MCF-7 cells were seeded in each well a 96-well plate at the optimal cell 
concentration per well, as determined from the standard curve for each cell line. Cells 
were treated with serial dilutions O.OOl-lOuM conventional (CrEL) taxol. Untreated cells 
were used as a control. All cells were cultured and absorbance values were quantified as 
previously discussed (section 4.6). Empty wells containing medium and MTT only were 
used as a blank and subtracted from absorbance values. Absorbance values for treated 
cells were reported as a percentage o f the untreated cells.
Part 2: Characterization o f  Liposomes
4.8 Preparation o f  liposomal paclitaxel:
Paclitaxel, phospholipids and in some cases cholesterol were dissolved in a 50 ml 
round-bottomed flask and dried with a rotary evaporator (Buchi Rotavapor R 205) at a 
temperature above the Tc o f  phospholipids (i.e 33 °C for DMPC, 50 °C for DPPC and 65 
°C for DSPC) under controlled vacuum (370 mbar) (Buchi Vacuum Controller V-800,
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Brinkman, Toronto, ON, Canada) and flashed with a nitrogen stream to eliminate traces 
o f chloroform. Briefly, phosphatidylcholine (DMPC; DPPC; DSPC) and 
phosphatidylglycerol were mixed at a 9:1 molar ratio and paclitaxel was added to a final 
ratio o f  3.33 mol % with respect to total phospholipids. The lipid/paclitaxel film was 
hydrated with 2 ml o f  phosphate buffered saline and sonicated for 2 min (cycles o f 15 
min run and 15 min pause) (Sonics & Materials VC 50). To remove non-incorporated 
paclitaxel, the liposome solution was submitted to centrifugation at 18,000 x g for 10 
min. In these conditions, small-sized liposomes remained suspended in the solution while 
free paclitaxel and large vesicles precipitated. The liposomal paclitaxel was then dialyzed 
overnight against PBS at 4°C with agitation to remove excess o f  unincorporated drug. 
The size distribution o f liposomes was monitored by photon correlation spectroscopy 
using a Malvern 3000HS Zetasizer with He-Ne laser. The measurements were taken at 
room temperature at wavelength o f 633.0 nm and 90° collecting optics.
4.9 Quantification o f  paclitaxel
The amount o f  paclitaxel incorporated in liposomes was determined by reversed 
phase HPLC. Drug content analysis was performed using a Symmetry C 18 column 
(Waters Nova-Pak C l8 column) with a mobile phase containing a mixture o f acetonitrile, 
water, and methanol (58:37:5, v/v/v) at a flow rate o f 1 ml/min. Sample injection 
volumes were 20 pi and paclitaxel detection was performed using UV detector at a 
wavelength o f 232 nm. Total run time was set to 5 min and paclitaxel retention time was
2.5 min. Peak area was recorded and processed.
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Briefly, small amount o f liposome solution (100 pi) which contained entrapped 
paclitaxel was destroyed by acetonitrile solution (900 pi). After sonication and 
centrifugation, the supernatant was subjected to HPLC for quantification o f entrapped 
drug. The equation (2) can be used to calculate the entrapment efficiency.
(2) Drug entrapment efficiency = (Drug entr / Drug total) x 100
4.10 Drug release study
Paclitaxel leakage from liposomes was determined by a dialysis method. Briefly, 
2 ml o f liposomal paclitaxel was transferred into dialysis bags and dialyzed against 500 
ml PBS with agitation at 37 °C. Each day the dialysis bags were transferred into new  
bottles containing 500 ml o f  PBS. Paclitaxel released from liposomes was successfully 
extracted with DMSO. The solvent was removed by nitrogen gas and the samples were 
reconstituted with 1ml acetonitrile and analyzed for drug content by HPLC method. 
Liposomal sizes were monitored throughout the release study using monitored by photon 
correlation spectroscopy using Malvern 3000HS Zetasizer with He-Ne laser and 90° 
collecting optics.
4.11 Rehydration o f  DPPC: DMPG liposomes:
Liposomes were composed o f 38 mg DPPC:4 mg DMPG. DMPG, dimyristoyl 
phosphatidylglycerol was added to increase the stability o f liposomes, consequently 
reducing the leakage o f  taxol from the liposomal formulation). Liposomes were 
maintained in a dehydrated lipid film for long-term storage at -20°C to retain stability. To 
rehydrate the lyophilized liposomes for use, 100 pi o f sterilized water was added and the
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mixture was vortexed until all powder was dissolved. After 15 minutes at 45°C, 100 pi o f  
PBS was added, and the sample was placed back at 45°C for additional 30 minutes. 
300pL o f PBS was added for a final volume o f 500 pL. The mixture was vortexed 
throughout the procedure to ensure uniform composition and to eliminate any large 
clumps. The mean size o f the liposomes after rehydration was 155nm, as determined by 
photon correlation spectroscopy using the Malvern 3000HS Zetasizer with He-Ne lazer 
and 90° collecting optics.
4.12 Toxicity o f  Liposomes:
The MTT cytotoxicity assay was used to determine the toxicity o f  empty 
DPPC:DMPG liposomes on MCF-7 cells, as well as on the non-cancerous cell line, HSF- 
55. This study was carried out to ensure whether the lipid components o f the liposomes 
contributed to the toxic effects o f taxol.
Part 3: Evaluation o f  the effects o f  CrEL vs. liposomal taxol
4.13 DNA isolation
Cells were pelleted by centrifugation at 2000Xg and at 4°C. The medium was 
removed and the cells were resuspended in 100 pi nuclei buffer (Appendix A). After 10 
minutes at 4°C, nuclei were pelleted by centrifugation at 10000 rpm for 5 minutes and 
4°C. One hundred pi o f phenol was added to the cytoplasmic fraction and was 
centrifuged at 14000 rpm for two minutes. The pellet was resuspended in 5 pi o f 5 M 
NaCl, 15 pL sodium acetate, and 200 pi o f  100% cold ethanol, and DNA was allowed to 
precipitate for at least 24 hours at -20°C.
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4.14 DNA fragmentation assay:
DNA fragmentation is a known hallmark biochemical change induced by taxol 
(Au, Kumar, Li, & Wientjes, 1999). To determine the level o f  DNA fragmentation in 
MCF-7 cells, 5.0 x 10  ^cells were seeded in a 10 cm plate for each treatment or control 
sample. Cells were treated with serial concentrations o f 0.1-10 uM liposomal or 
conventional taxol. Cells incubated without any liposomes or drugs were used as 
controls. After 72 hours incubation, DNA was isolated from floating cells as described 
above (section 4.13). Following precipitation o f DNA, samples were centrifuged at 
11800 rpm for 15 minutes at 4°C. DNA pellets were resuspended in 20 pi o f water and 
separated on a 1.6% (w/v) agarose gel. DNA degradation was viewed and assessed 
visually with a UV transilluminator.
4.15 Flow cytometric cell cycle analysis o f  taxol-treated cells:
Flow cytometry is widely used to analyse the cell cycle o f mammalian cells 
(Nunez, 2001; Potter et al., 2002). Cells were plated at a density o f  75% confluence in a 
100 mm dish and serial dilutions o f taxol were added to the plates. The cells were 
incubated for 1-7 days, at which point the adherent cells were trypsinized and pooled 
together with floating cells. The floating cells were included in the analysis in order to 
accurately quantify cell death, as these cells have been shown to be crucial in the analysis 
o f apoptosis (Turco, De Angelis, Stammati, & Zucco, 2000). After being centrifuged at 
200Xg for 6 minutes, the supernatant was removed and the cell pellet was resuspended in 
0.5 ml PBS. Next, MCF-7 cells were put through a 25 gauge syringe to ensure a uniform, 
single-cell suspension. This step was not necessary for A549 cells, as they naturally form
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a single-cell suspension upon trypsinization. Next, 4.5 ml o f  70% (v/v) ethanol fixative 
was added to each tube containing PBS while the mixture was vortexed. Cells were 
stored at 4°C until staining and analysis for flow cytometry, at which point ethanol- 
suspended cells were centrifuged for 5 minutes at 200Xg. The ethanol was decanted and 
the cell pellet was resuspended in 5 ml PBS with 0.1% SDS. Next, 9 pi o f propidium 
iodide (PI) staining solution [1 mg/ml PI, lOmg DNase-free RNase, 10 ml 0.1% (v/v) 
Triton X-100 in PBS] was added, and samples were incubated for 15 minutes at 37°C 
before analysis by flow cytometry (FACS; BD Biosciences).
Flow cytometry data were collected and analyzed using CellQuest Pro software 
(BD Biosciences). Control samples were used to determine and set gates for cell cycle 
analysis (sub-Gl, G o/G l, S, G2). The same software was used to determine the number 
o f cells in each phase o f the cell cycle, as well as the percentage o f the total cells acquired 
in each region, based on the gates. P-values were obtained by performing unpaired 
Student’s t-tests between data for G2 /M and sub-Gl following CrEL and liposomal 
treatments.
4.16 Determination o f  mitotic index:
The mitotic index was determined to verify flow cytometry data and to 
differentiate between cells in G2  and those in mitotic arrest induced by taxol. This is a 
common technique used to quantitate the effects o f taxol and other mitotic-inhibitor 
agents (Calastretti et ah, 2001; Kamath et ah, 2005; Schmidt et ah, 2000). Cells were 
plated on glass coverslips in each well o f a 6-well dish and allowed to adhere overnight. 
The following day, they were treated with 1 or 10 uM taxol for 24 hours. Treatment
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length was determined by flow cytometry in order to determine a time-point where cells 
were still adherent and predominantly in G2  arrest (Potter et al., 2002). Untreated cells 
were used as controls. Following treatment, the cells were fixed with ice-cold methanol. 
The cells were stained with Ipg/ml 4 ’,6-diamindino-2 phenylindole (DAPI) and mounted 
onto a microscope slide in mounting medium (90% (v/v) glycerol, 10% (v/v) 1 X PBS, 
containing 1 mg/ml p-phenylenediamine). Epiflourescence microscopy (Zeiss, North 
York, ON, Canada) was used to count a minimum o f 500 cells per treatment and mitotic 
figures were scored. Mitotic figures were classified based on the appearance o f  
chromatin condensation, and separation o f discrete DNA molecules (Wang et al., 2005). 
P-values were obtained by performing unpaired Student’s t-tests between data for CrEL 
and liposomal treatments.
4.17 Ultra-Performance Liquid Chromatographic analysis (UPLC) o f  relative taxol 
uptake:
Cells were plated at a density o f 5 x 10  ^ cells per 10 cm plate and treated with 10 
pM liposomal or conventional paclitaxel. Plates were left to incubate for 24 hours, after 
which media was removed, cells were rinsed twice with PBS, trypsinized, and and 
resuspended in media. Twenty ul o f each sample was diluted in trypan blue dye. These 
were counted using a haemocytometer and brightfield microscopy to determine a total 
cell count for each sample. Next, the cells were pelleted at 3000 rpm for 10 minutes 
(Eppendorf). The supernatant was removed, and the cell pellet was frozen at -20°C until 
analysis. Cell pellets were thawed and resuspended in 100 pi mobile phase (58% (v/v)
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acetonitrile, 37% (v/v) H2 O, and 5% (v/v) methanol) for analysis by ultra-performance 
liquid chromatography (UPLC; Waters).
Next, cells were sonicated at 75% intensity for 3 minutes to release taxol from the 
cells. Cell debris was pelleted at 14000 rpm for 2 minutes. Taxol was extracted according 
to a modified protocol developed by Yonemoto et al. 2007. Briefly, the supernatant, 
containing taxol, was transferred to a new tube and 1ml tert-butylmethyl ether (t-BME) 
was added. Samples were vortexed for one minute, then centrifuged for an additional 5 
minutes at 1700 rpm. The organic supernatant was removed and transferred to a new 
tube. The t-BME was evaporated and residue was re-dissolved in 100 pi mobile phase. 
Samples were separated through a reverse-phase column (C l8, 1.7 pm, bead diameter 1.0 
X 50 mm; Waters) and analyzed at a wavelength o f 229 nm at a flow rate o f 0.25 ml/min. 
Data was analyzed using Waters Acquity software.
4.18 MTT analysis o f  the role o f  caspases in taxol-induced apoptosis:
To further elucidate the mechanism o f cell death induced by taxol in MCF-7 
breast cancer cells, the MTT cytotoxicity assay was used to test the efficacy o f  caspase- 
inhibitors as apoptosis-inhibitors (Yano et al., 2007). Caspases are important components 
o f apoptosis and execution pathways, and have been shown to play a role in 
chemotherapy-induced cell death (Janicke et al., 1998; Ofir et al., 2002; S. J. Park et al., 
2004). Cells were seeded in a 96-well plate and treated with taxol in combination with the 
caspase-inhibitors C l (Caspase inhibitor 1: pan-caspase inhibitor o f  all caspase-l-like 
proteases; Calbiochem) or C3 (Caspase 3 inhibitor 1: inhibits caspases 3,6,7,8,10 & 
PARP cleavage; Calbiochem). Cells treated with the caspase-inhibitors or taxol were
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used as controls. All absorbance values were reported as a percentage o f  the untreated 
control sample.
4.19 Western Blot analysis o f  P-glycoprotein (P-gp) in MCF-7 cells:
MCF-7 cells were seeded in a 100 mm plate at a density o f  5x10^ or 7x10^ cells 
per plate for untreated and treated samples, respectively. After adherence, cells were 
treated with 10 pM taxol or fresh medium for an additional 48 hours. Cells were 
trypsinized and pelleted and 400 pi 2x sodium dodecyl sulphate (SDS) buffer was added 
to lyse the cells. Samples were boiled for 15 minutes and stored at -20°C until analysis. 
Next, samples were boiled for 15 minutes, and 25 pi o f each sample was loaded and 
separated by 10% (w/v) SDS-PAGE at 160 V. Protein was transferred to PVDF 
membrane at 30 V  overnight at 4°C. The membrane was probed with C219 mouse 
monoclonal 1° antibody (Signet) at 4°C overnight. The membrane was rinsed four times 
with TEST then probed again with anti-mouse 2° antibody (Sigma). After another four 
rinses, the blot was rinsed in exposing solution and a film was exposed in the dark for 5 
minutes and developed using an x-ray developer.
4.20 Statistical Analysis
The results were expressed as means ±  SEM obtained from three separate 
experiments. Comparisons were made by paired Student’s t-test, and a P  value o f 0.05 or 
less was considered significant.
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V . Results:
Part 1. Establishment o f a taxol-resistant MCF-7 clone
Successive taxol treatments were used to establish taxol-resistant colonies of 
MCF-7 cells. In order to determine the length o f a cell cycle and to characterize taxol- 
resistant cell lines in comparison to their parental counterparts, growth rates were 
calculated through a cell counting experiment (Figure 11). The doubling time for wild- 
type MCF-7 cells was 29.25 hours, which is the same as the ATCC value o f 29 hours 
(Table 2; ATCC product information sheet, MCF-7 cells). A resistant sub-clone o f the 
MCF-7 cells developed in our laboratory for this study had a similar doubling time to its 
wild-type counterpart (26.56 hours; Table 2). Elowever, MCF-7 cells obtained from Dr. 
Parissenti had a significantly slower growth rate than this lot o f  cells (wild-type B, 38.09 
hours). In addition, resistant cells derived from this cell line (tax-resistant) had a much 
slower growth rate than their wild-type counterparts (Tax-resistant, 50.23 hours; Guo et 
al, 2004). It is recognized that resistant cell lines typically have longer doubling times 
than their parental derivatives (35).
Doubling times were used as the length o f  a cell cycle for a colonization assay. In 
turn, this information was used to compare and characterize potentially taxol-resistant 
MCF-7 clones to their wild-type derivative (wild-type A), as well as to another MCF-7 
strain (wild-type B) and another taxol-resistant MCF-7 cell line (tax-resistant). Cells 
were treated for two cell cycles, as determined from the doubling time, at which point 
they were allowed to recover in fresh medium. The number o f colonies formed was 
counted and used to differentiate between potentially taxol-resistant colonies isolated
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following successive taxol treatments, and those that were not resistant. Results for the 
most resistant clone are shown and compared to the two wild-type MCF-7 cell lines as 
well as the tax-resistant cell line (Figure 12). The MCF-7 clones isolated and selected 
from these experiments for their resistant properties were then used to test the efficacy o f  
liposomal and conventional formulations o f taxol, and to determine if  liposomal 
encapsulation o f taxol could enhance its ability to overcome resistance mechanisms in 
these cells.
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Figure 11: Growth rate o f  wild-type and taxol-resistant MCF-7 cell lines.
Cell Line Doubling time (hours)
W ild-type A  
C lone 
W ild-type B 
Tax-resistant
2 9 .2 5  +/- 0 .32  
2 6 .5 6  + / - 0 .1 8  
3 8 .0 9  +/- 0 .53  
5 0 .23  +/- 0 .67
Table 2: Comparison o f doubling-time 
between wild-type MCF-7 cell lines and 
their taxol-resistant derivatives, as 
determined from growth curves.________
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Figure 12: Colony counts after taxol treatment for 2 cell cycles and 3 weeks 
growth time.
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Three strains o f  MCF-7 breast cancer cells were treated with a serial dilution o f  
taxol for 4-days to determine and compare their sensitivity to the drug and to determine 
suitable concentrations o f  the drug for analysis with other assays. Standard curves were 
used to determine optimal plating density for 3 strains o f MCF-7 breast cancer cells 
(wild-type A, clone, and tax-resistant) for the MTT cytotoxicity assay (Figure 13). 
Plating densities were determined by selecting a cell coimt coinciding with linear 
sensitivity o f  the MTT assay, with a preferable absorbance higher than 0.7 and lower than 
1.25 (Table 3).
Wild-type MCF-7 cells had the lowest IC5 0  (0.008 pM; Table 4), followed by a 
taxol-resistant clone (0.044 pM; Table 4). The tax-resistant cell line had the highest IC5 0  
of the three strains o f  MCF-7 cells (Table 4). Interestingly, the taxol-resistant clone was 
not highly resistant at lower concentrations, but did not show a linear response to taxol at 
higher concentrations. These results suggest a role for induced activation and expression 
o f resistance genes, such as M D R l, by taxol at higher concentrations in this cell line and 
that concentrations o f  taxol o f  at least 0.1 pM are needed to cause significant cytotoxicity 
in MCF-7 cells (Figure 14). As a result, concentrations ranging from 0.1-10 pM were 
used in subsequent analyses.
56
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Standard Curve - Fr clone 24h
10 15 20 25
# Cells/Well ( I f )
Standard Curve - Fr clone 4  days
a  0.4
10 15 20 25
#  Cells/well (X I O’)
Standard Curve - Tax-resistant MCF-7 24h standard  Curve - Tax-resistant MCF-7 4 days
0 5 10 15 20 25 30 35
#  Cells/well (10*)
1—■*——1-------r
10 IS 20 25 30
#Cells/weli(10»)
Standard Curve - MCF-7 wild-type 24h Standard Curve - MCF-7 wild-type 4-day
1 “
I
I
_________ j
Ï I 4 — — T
■ ~ i
N N w d B B # ............. ...!
V
10 15 20 25 30
#Cells/w«ll(x10’) 10 15 20 25 30 95#Cells/weH(x1Q*)
Figure 13: Standard curves for MCF-7 cancer cells to optimize initial cell densities for two 
end points using the MTT cytotoxicity assay.___________________________________________
Cell line End-point Optimal seeding density 
(days)______________(xlO^)_________
MCF-7 clone 1 25
MCF-7 clone 4 2.5
Tax-resistant 1 3
Tax-resistant 4 2.5
Wild-type 1 10
Wild-type 4 4
Table 3: Optimal plating densities for cell lines used in this 
study for 1 -day and 4-day end-points using the MTT 
cytotoxicity assay.______________________________________
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Figure 14; MTT analysis o f  3 strains o f  MCF-7 breast cancer 
cells after 4 -day treatment with taxol.
Table 4: IC5 0  values for MCF-7 strains
treated with taxol for 4 days as determined
from MTT analysis.
Cell line (MCF-7) IC5 0  (m-M)
Wild-type 0.008
Resistant clone 0.044
Taxol-resistant 0.186
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Part 2: Characterization o f Liposomes
HPLC analysis was used to determine the cumulative release o f taxol from three 
different formulations o f  liposomes over a period o f four days (Table 5; Figure 15), as 
well as the stability o f  the liposomes (Figure 16). The stability o f  the liposomal taxol 
formulation is a percentage determined from the cumulative release, and it is important as 
it directly affects the half-life o f the drug on the shelf, as well as the delivery o f  the drug 
to its target. These assays were used to determine the optimal formulation o f liposomal 
taxol for storage and delivery o f the drug. All three formulations, namely, DSPC-DMPG 
liposomes, DPPC-DMPG liposomes, and DMPC-DMPG liposomes retained comparable 
amounts o f  taxol (>97%, >95%, and >93% o f taxol, respectively) (Figure 15).
Liposomes were analyzed by photon correlation spectroscopy throughout these 
studies. Taxol retention in liposomes can partially be attributed to liposome size, as the 
larger the liposome, the better the stability and taxol retention. The DPPC-DMPG 
liposomes were selected as the most favourable delivery method based on stability 
studies. The size distribution o f this liposomal formulation is shown (Figure 17). A 
comparison o f  stability and mean size o f  the liposomal taxol formulations is summarized 
in Table 5.
MCF-7 and HSF-55 cells were treated with increasing concentrations o f empty 
DPPCiDMPG liposomes for a period o f 1-3 days to determine inherent toxicity o f  the 
lipids to cancer cells (MCF-7) , as well as to non-cancerous tissue (HSF-55). An MTT 
assay was performed and the values were averaged for both cell lines. The liposomes 
were not found to be toxic, with >80% survival at the highest concentration (20 pl/ml; 
Figure 18).
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Table 5: Full names o f liposome formulations used in this study
Liposome Full name o f fatty acid component
DMPC-DMPG dimyristoyl phosphatidylcholine; dimyristoyl phosphatidylglycerol
DPPC-DMPG dipalmytoyl phosphatidylcholine; dimyristoyl phosphatidylglycerol
DSPC-DMPG______ distearoyl phosphatidylcholine; dimyristoyl phosphatidylglycerol
I k
® D M PC-D M PG -PTX  
■  DPPC-D M PG -PTX  
□  DSPC-D M PG -PTX
Time|days|
Figure 15; Cumulative release o f  paclitaxel (pg) from three formulations o f liposomal taxol 
in phosphate buffer at 4°C.
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Figure 16: Stability o f  three formulations o f liposomal taxol in phosphate buffer at 4°C 
as determined by HPLC analysis._________________________________________________
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S iz e  distribution{s)
100 500
Diameter (nm)
Figure 17; Size distribution o f DPPC;DMPG liposomes as determined by 
photon correlation spectroscopy. Mean size = 155.7 nm.________________
Liposomes Size (nm) Poly. Ind. Enc. Eff. (%)
DMPC-DMPG-PTX
DPPC-DMPG-PTX
DSPC-DMPG-PTX
143.07 ± 8 .36  0.36 ±0.01  
156.57 ± 3 .5 8  0.39 ± 0.06 
184.93 ± 12.87 0.40 ± 0 .05
96.10 ±2.21  
96.14 ± 5 .77  
70.18 ± 4 .38
Table 5: Size distribution and encapsulation efficiency o f liposomal taxol 
formulations as determined by photon correlation spectroscopy (PCS) and high 
performance liquid chromatography (HPLC).
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Figure 18: MTT cytotoxicity assay o f MCF-7 and HSF-55 cell lines treated with 
increasing concentrations o f  DPPCiDMPG liposomes for 1, 2 or 3 days.
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Part 3 : Evaluation o f the effects o f  CrEL vs liposomal taxol
Taxol is known to cause mitotic arrest, leading to cell stress, and eventually 
cell death, or apoptosis (Moos and Fitzpatrick, 1998). In order to evaluate the effects o f  
the two taxol forms, namely conventional (CrEL) and liposomal (liptax) on MCF-7 breast 
cancer cells, flow  cytometric analysis o f the cell cycle was used to determine the 
percentage o f  cells in 0% or mitotic arrest, as well as the percentage o f  cells with 
degraded (sub-Gi) DNA. Mitotic indexes were also calculated to quantify and confirm 
the mitotic arrest induced by taxol, and DNA fragmentation analysis was used to 
determine the degree o f  apoptosis.
Flow cytometric analysis o f MCF-7 cells treated with liposomal (liptax) or 
conventional (CrEL) taxol over a 7-day period was conducted to compare the 
effectiveness o f  the two formulations. Liposomal taxol treatment o f  wild-type MCF-7 
cells demonstrated a slight increase in Ga arrest when compared to the conventional 
formulation, up until 3-days incubation with the drug (Table 6a, Figure 19a). After this 
time-point, the liposomal formulation caused increased DNA degradation, which is 
indicative o f  cell death. This effect was seen most notably after 7 days incubation (68 
versus 37% sub-Gl; Table 6a). Similar results were also seen following exposure o f the 
clone cells and the tax-resistant MCF-7 cells to liposomal taxol (Tables 6b, 6c; Figures 
19b, 19c).
Overall, this study revealed that liposomal taxol (liptax) caused Gz arrest after 
shorter drug incubation lengths, and a greater percentage o f cells underwent cell death 
(sub-Gi cells) when compared to cells treated with conventional (CrEL) taxol. These 
effects were most prominent in a taxol-resistant clone.
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% Total
Region control day 1 CrEL
day 1 
liptax
day 3 
CrEL
day 3 
liptax
day 5 
CrEL
day 5 
liptax
day 7 
CrEL
day 7 
liptax
sub-Gl 8.15 3.78 8.98* 39.18 20.90* 16.42 44.04** 36.56 67.80**
Gl/GO 59.30 24.88 14.78 15.72 10.19 19.49 7.87 15.28 5.57
S 9.11 8.29 6.75 4.83 9.81 11.95 7.00 9.12 5.35
G2/M 20.16 62.72 69.21 40.22 58.84* 52.45 40.70* 39.07 21.01*
Table 6a: Flow cytometric analysis o f cell cycle -  wild-type A MCF-7 cells treated 
with 10 |iM conventional taxol (CrEL) or Liposomal taxol (liptax). * indicates a 
significant difference between liposomal and CrEL treatments with p<0.05 
according to Student’s t-test. ** indicates p<0.01.
% Total
Region control day 1 CrEL
day 1 
liptax
day 3 
CrEL
day 3 
liptax
dav 5 
CrEL
day 5 
liptax
day 7 
CrEL
day 7 
liptax
sub-Gl 1.88 11.22 9.39 9.73 19.17* 13.51 46.28** 30.42 69.81**
Gl/GO 78.28 42.64 30.95 42.05 22.66 41.54 15.15 33.98 10.30
S 7.06 6.07 8.79 5.75 6.21 4.29 5.00 4.19 3.62
G2/M 12.68 39.69 50.31 42.59 51.76* 40.52 33.02* 31.42 15.82*
Table 6b: Flow cytometric analysis of the cell cycle at different time points. Taxol-resistant 
MCF-7 clone cells were treated with 10 pM conventional taxol (CrEL) or Liposomal taxol 
(liptax). * indicates a significant difference between liposomal and CrEL treatments with 
p<0.05 according to Student’s t-test. ** indicates p<0.01.______________________________
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% Total
Region control day 1 CrEL
da\ 1 
liptax
day 3 
CrEL
day 3 
liptax
day 5 
CrEL
day 5 
liptax
day 7 day 7 
CrEL liptax
sub-Gl 18.08 32.17** 9.73 19.17** 13.51 46.28** 3 0 .42  6 9 .81**
Gl/GO 78.28 33.97 30.95 42.05 22.66 41.54 15.15 33.98 10.30
S 7.06 9.71 8.79 5.75 6.21 4.29 5.00 4.19 3.62
G2/M 12.68 37.72 50.31 42.59 51.76 40.52 33.02 31.42 15.82*
Table 6c: Flow cytometric analysis o f  cell cycle at different time points. Taxol- 
resistant cells were treated with 10 pM conventional (CrEL) or Liposomal taxol 
(liptax). * indicates a significant difference between liposomal and CrEL treatments 
with p<0.05 according to Student’s t-test. ** indicates p<0.01.
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Figure 19a: Histograms showing the number o f cells in each phase o f  the cell cycle for 
wild-type MCF-7 breast cancer cells after treatment with 10 pM conventional (A) or 
liposomal (B) taxol over a 7-day period. Results are given for 1-day (D l), 3-day (D3), 
5-day (D5) and 7-day (D7) incubation lengths in taxol.
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Figure 19b: Histograms showing the number o f  cells in each phase o f  the cell cycle for 
clone MCF-7 breast cancer cells after treatment with 10 pM conventional (A) or 
liposomal (B) taxol over a 7-day period. Results are given for 1-day (D l), 3-day (D3), 
5-day (D5) and 7-day (D7) incubation lengths in taxol._______________________________
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Figure 19c: Histograms showing the number o f cells in each phase o f  the cell cycle for 
tax-resistant MCF-7 breast cancer cells after treatment with 10 pM conventional (A) or 
liposomal (B) taxol over a 7-day period. Results are given for 1-day (D l), 3-day (D3),
5-day (D5) and 7-day (D7) incubation lengths in taxol.______________________________
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Taxol is known to bind micro tubules, inducing mitotic arrest in cells that 
eventually leads to cell stress and cell death (Moos & Fitzpatrick, 1998). As a measure o f  
the effect o f  taxol on cancer cells, mitotic indexes were determined for wild-type and 
clone MCF-7 breast cancer cells treated with either CrEL taxol or liposomal taxol at 1 
pM or 10 pM for 24 hours.
These results can differentiate between the G2  and M (mitosis) phases o f the 
cell cycle as determined by flow cytometry, to further correlate taxol treatment with 
mitotic arrest. Under normal, untreated conditions, dividing mitotic figures were 
observed in all stages o f  mitosis, including metaphase, anaphase, and telophase (Figure 
20). In contrast, mitotic figures induced by taxol treatment were predominantly 
condensed chromosomes in metaphase.
MCF-7 breast cancer cells showed a significant increase in mitotic figures upon 
treatment with liposomal taxol when compared to CrEL taxol (Table 7). This increase 
was more dramatic at higher concentrations o f  taxol (10 pM). Mitotic indices were not 
able to be reliably determined for tax-resistant MCF-7 cells, as these cells tended to form 
foci as they grow, and nuclei appeared layered on top o f each other, even at low density. 
As a result, mitotic figures were not clearly visible, and total cell counts could not be 
ascertained.
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Table 7: Mitotic index of control and taxol-treated cancer cells
Taxol (uM)
Mitotic Index (%)
0 1-CrEL 1-Liptax 10-CrEL 10-Liptax
MCF-7 wild-type 5 26.2 39.2 11.1
MCF-7 clone 7.3 26.9 49.4 12.4
42.3**
52.3**
Mitotic indices were determined following 24 hour taxol treatment.
** indicates significant difference between CrEL and Liptax treatment, 
where p<0.01.______________________________________________
Figure 20: Wild-type MCF-7 breast cancer cells stained with DAPI and viewed under 
fluorescent light with a 40X objective under normal conditions (A), and after liposomal 
taxol treatment (B)_______________________________________________________________
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Following mitotic arrest, taxol is known to cause apoptosis (Moos & 
Fitzpatrick, 1998). DNA fragmentation is a known marker o f  apoptosis, and in certain 
cell types, cleavage o f  DNA into intemucleosomal fragments o f  ~  200bp can be 
visualized as a “DNA ladder” by gel electrophoresis (P. Huang, Robertson, Wright, & 
Plunkett, 1995).
MCF-7 breast cancer cells were treated with a range o f concentrations o f  
liposomal or conventional (CrEL) taxol, and DNA fragmentation was visualized by 
agarose gel electrophoresis (Figure 21a). This fragmentation was quantified and 
compared using computer analysis o f  gel bands. Results o f DNA fragmentation assays 
showed that wild-type MCF-7 cells had the greatest amount o f DNA fragmentation 
following treatment with taxol (26-36 mean CNT). However, there was no significant 
difference in the amount o f  fragmentation generated by either formulation.
There was a marked increase in DNA fragmentation in clone MCF-7 cells after 
treatment with 10 pM liposomal taxol for 4 days when compared to equivalent treatment 
with CrEL taxol. Tax-resistant MCF-7 cells had very little fragmentation with either 
formulation, and as a result, there was no significant difference when comparing 
treatment with the two formulations (Figure 21a, Figure 21b).
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Figure 21a: DNA laddering gel demonstrating DNA fragmentation in wild-type 
(A), clone (B), or Tax-resistant (C) MCF-7 cells treated with 0.1, 1, or 10 pM  
liposomal (Lipo) or conventional (CrEL) taxol.
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Figure 21b: DNA degradation (mean CNT density values) for individual lanes o f  a 
DNA laddering gel o f  three strains o f MCF-7 breast cancer cells treated with three 
concentrations o f CrEL or liposomal taxol._____________________________________
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In order to elucidate whether increases in taxol-induced changes in mitotic index, 
and apoptosis were related to the cellular concentration o f  taxol, the uptake o f  taxol, 
administered as a liposomal or conventional formulation by MCF cells, was measured by 
UPLC. The retention time o f taxol was 0.320 minutes, with a maximum absorbance at 
229 nm. A  standard curve was automatically generated using Acquity software (Waters) 
for UPLC analysis o f  taxol using three separate concentrations o f  the drug (data not 
shown). Concentrations lower than 0.4 pM were not able to be accurately quantitated 
using this calibration, and as a result, they are reported as “not determined” (ND) in 
Table 8. This standard calibration was used to quantitate the amount o f taxol in media 
and cell lysate samples treated for 24 hours with taxol.
The results from uptake studies revealed that the uptake o f  taxol by taxol-resistant 
cells was markedly higher in those cells challenged with liposomal (liptax). Media 
samples containing taxol were also analyzed after incubation with cells to determine 
residual taxol not taken up by cells after treatment. The results from those experiments 
showed that there was an association between changes in cellular levels o f taxol and 
those measured in the media (Figure 22, Table 8). More precisely, the residual taxol in 
the media o f  samples incubated with liposomal taxol were lower than those observed 
following incubation with CrEL (data not shown).
Similar results were found for all three strains o f MCF-7 cells, but interestingly, 
the most prominent difference was noted in the taxol-resistant cell lines (Figure 22). 
Samples that were not treated with taxol were used as a control to ensure that no 
components found in the media, buffer, mobile phase, or cell lysate interfered with the 
taxol peak eluting at 0.320 minutes.
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Figure 22: UPLC chromatogram showing the level o f  taxol uptake o f  taxol-resistant 
cells treated with 10 pM taxol for 24 hours.______________________________________
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Sample Taxol
treatment
Retention 
time (RT)
Peak
Area
Amount
(pM)
Total #
cells
(xlO^
Taxol 
(pM) per 
1x10® cells
Tax control Untreated 0.320 N/A ND 1.5 ND
Tax Liptax 0.321 730098 7%SW8 0.9 &89
Tax CrEL 0.320 60301 ND 0.9 ND
Clone Liptax 0.322 1271345 19.305 2.7 7.15
Clone CrEL 0J21 46472 ND 2.8 ND
Table 8; Taxol uptake as c 
not be detected (ND) belo\
etermined from UPLC c 
V 0.4 pM.
iromatograms. Amounts could
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To further elucidate the mechanism o f cellular resistance to taxol in drug- 
resistant MCF-7 cells, the resistance protein encoded by M D R l, p-glycoprotein (P-gp) 
was assessed. Western blot analysis o f  MCF-7 cells detected the presence o f  the P- 
glycoprotein membrane pump commonly implicated in multidrug resistance. However, 
the protein was only detectable in a taxol-resistant cell line, and not in wild-type MCF-7 
cells or a taxol-resistant MCF-7 clone (Figure 23). In addition, there was no difference in 
the level o f expression in cells that were treated with taxol than the level o f  expression in 
untreated cells o f  the same cell line, suggesting that this pump is consistently expressed 
in these cells, and is not induced or upregulated by taxol treatment.
To further analyze the mechanism o f cell death induced by taxol and to determine 
i f  the common apoptosis pathway involving the caspase signaling cascade is induced by 
the drug, an MTT cytotoxicity assay was performed on cells treated with taxol in 
combination with caspase inhibitors. The combination o f caspase inhibitors and taxol had 
no effect on taxol-induced cell death, yet treatment with caspase inhibitors impacted 
spontaneous apoptosis, resulting in an increase in absorbance in these cells compared to 
untreated cells (Figure 24). This suggests that the predominant pathway o f  apoptosis in 
cycling MCF-7 cells involves the cleavage o f  caspases. However, taxol induces an 
alternate apoptotic pathway, and as a result, analysis o f caspase activity is not an 
appropriate measure o f taxol-induced cell death.
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Figure 23: Western blot analysis o f  MCF-7 cells stained with an antibody for the 
P-glycoprotein membrane pump.
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In order to determine the effect o f  liposomal taxol on other cell types 
commonly treated with taxol, A549 lung cancer cells were analyzed for their response to 
liposomal taxol in comparison to conventional CrEL taxol. Preliminary studies o f  
cytotoxicity, cell death, and mitotic arrest were performed. Cytotoxicity was analyzed by 
MTT assays, which were standardized and performed after 24 hours and 5 days o f  
incubation with the two formulations o f taxol (Figure 25, Table 9, Figure 26). The results 
o f this assay did not demonstrate any notable difference between the two formulations.
Flow cytometric analysis o f the cell cycle was carried out to compare the level 
o f G2 arrest and DNA degredation in the lung cancer cells following 24 hours o f  1 pM or 
10 pM taxol treatment (Figure 27, Table 10). After 1 pM taxol treatment, the two 
formulations had nearly identical effects on the lung cancer cells. However, after 10 pM 
taxol treatment, there was increased G2 arrest (80.90 versus 64.34%), and DNA  
degredation (sub-Gl; 10.61 versus 5.33%) in the cells treated with liposomal taxol in 
comparison to those treated with conventional CrEL taxol (Table 10). These preliminary 
data suggest that the liposomal taxol might be more advantageous than the conventional 
treatment in the chemotherapy o f lung adenocarcinoma.
The mitotic index was also determined for A549 lung cancer cells after 24 
hour treatment with I pM or 10 pM taxol. Results from this assay demonstrated a 
similar outcome, as liposomal taxol caused increased mitotic index in these cells, and a 
greater difference was noticed at the higher concentration o f taxol (Table 11).
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Figure 25: Standard curves for A549 lung cancer cells to optimize initial cell densities 
for two end points using the MTT cytotoxicity assay._________ _____________________
Cell line End-point Optimal seeding density 
(days)______________(xlO^)_________
A j49
A549
25
15
Table 9: Optimal plating densities for A549 lung cancer cells 
analyzed at 1-day and 5-day end-points using the MTT 
cytotoxicity assay._______________________________________
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igure 26: MTT o f A549 lung cancer cells -  24h and 5-day treatment 
with taxol.
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Figure 27: Flow cytometric analysis o f  A549 lung cancer cells treated with CrEL 
(A,C,E) or liposomal (B,D,F) taxol for 24 hours (A,B,C,D), or 5-days (E,F). All samples 
were treated with 1 pM taxol, with the exception o f C and D, which were treated with 
10 uM.___________________________
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% Total
Region control
24h 1 
1 pM 
CrEL
24h
IpM
liptax
24h
lOpM
CrEL
24h
lOpM
liptax
sub-Gl Z63 12.01 13.74 5J3 10.61
Gl/GO 71.61 6.42 4.65 27.31 5 j g
S 82u 4.16 2.28 , 2.49 : :L53
G2/M 17.65 77.13 78.45 64.34 80.9
Table 10: Preliminary flow cytometric cell cycle analysis 
o f A549 lung cancer cells treated for 24h with 1 or 10 pM 
conventional (CrEL) or liposomal (liptax) taxol._________
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Table 11: Mitotic index of control and taxol-treated cancer cells
Mitotic Index (%)
Taxol (mM)__________ 0 1-CrEL 1-Liptax 10-CrEL 10-Llptax
A549 lung cells 3.9 68.2 74.2 46 1 56.5*
Mitotic indices were determined following 24 hour taxol treatment.
* indicates significant difference between CrEL and Liptax treatment, 
where p<0.05._____________________________________________
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VIL Discussion
A new formulation o f liposomal taxol was developed in an attempt to explore 
alternatives to the current Cremophor EL (CrEL) vehicle, which is known to exert several 
adverse effects, including anaphylactic shock (Gelderblom et al., 2001; Gelderblom et al., 
2001; Sparreboom et al., 1999; van Tellingen et al., 1999). Two taxol-resistant MCF-7 
cell lines (tax-resistant and clone) were used to test the efficacy o f  liposomal taxol in 
comparison to the conventional CrEL formulation, as well as to determine whether 
liposomal eneapsulation would circumvent the resistance mechanisms expressed by these 
cells. The two formulations were also tested on the parental wild-type MCF-7 cells, 
which are inherently sensitive to the drug.
A taxol-resistant MCF-7 clone was established through successive treatments 
with high concentrations o f taxol over a period o f several months. This clone had 
distinctive differences in growth eharacteristics, morphology, and sensitivity to taxol 
when compared to the parental strain o f  MCF-7 eells. Specifically, it had a shorter 
doubling time, cells appeared smaller in size and grew more densely in culture, and it 
displayed a non-linear response to taxol at concentrations >0.0luM. Another taxol- 
resistant MCF-7 cell line kindly provided to us by Dr. Parissenti also displayed altered 
growth characteristics, morphology, and taxol sensitivity (Guo et al., 2003; Guo et al., 
2004; Villeneuve et al., 2006). However, there were differences between these two 
resistant lines. The tax-resistant line had a longer doubling time, and the cells appeared 
larger and less dense than the wild-type cells. These effects are not unusual, as altered 
morphology and growth charaeteristics have been encountered in other ehemoresistant
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cell models (Li et al., 2004). However, these taxol-resistant eells were highly resistant at 
lower concentrations, but not at higher concentrations.
The differences between the two taxol-resistant cell lines may be explained by 
the differences in the methodology used to create them. The tax-resistant cell line was 
treated with successive inereasing doses o f  taxol until a maximum tolerated dose o f  6 . 6  
nm was reached (Guo et al., 2004). In contrast, the resistant clone was grown at an initial 
concentration o f 7.5 pM taxol, followed by long-term incubation at 1 pM. As a result, the 
tax-resistant line was highly resistant at concentrations less or equal to 0.01 pM, while 
the clone had resistant properties at concentrations up to at least 10 pM. Because these 
two cell lines were distinct in their properties, it is quite possible that they express 
different genes and their resistant phenotypes function through different meehanisms. 
Indeed, genetic variability in apoptosis regulatory genes has been shown to eontribute to 
variability in drug response (Fulda et al., 2003). As a result, both eell lines were used to 
compare the efficacy o f liposomal taxol in comparison to conventional taxol, and more 
precisely delineate whether liposomal eneapsulation o f taxol could confer enhance 
chemotherapeutic effects o f taxol to both taxol-resistant cell lines.
Liposomes eomposed o f the lipids DPPC, DSPC, DMPC and DMPG were 
characterized with regards to their average size, taxol eneapsulation efficiency, stability, 
and toxicity. The liposomes used in our studies were small unilamellar liposomes with an 
average diameter o f approximately 156 nm (Figure 17). Liposomes o f  this size are 
readily taken up by cells by diffusion, allowing for efficient delivery o f their eontents 
(Figure 7; Hashimoto et al., 1992). Results from stability studies showed that DPPC- 
DMPG liposomes can be stored in a dehydrated powder form for months at a temperature
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o f -20°C (Figure 16). Upon rehydration, this formulation o f liposomal taxol is highly 
stable in phosphate buffer when stored at 4°C, as >95% o f taxol was still encapsulated 
after 4 days (Figure 15). The results from these studies indicate that our liposomal 
formulation would be suitable for use in the elinic, as the drug ean be shipped and stored 
in dehydrated form, then rehydrated when ready for administration. Furthermore, 
cytotoxieity studies showed that the liposomes themselves are non-toxic to cells, even at 
high doses (Figure 18). These results suggest that this formulation would be safe for 
delivery o f  taxol in vivo.
Flow cytometric analysis o f  the cell eyele o f the 3 MCF-7 cell lines 
demonstrated that liposomal taxol was able to cause increased G2 /M arrest at earlier 
treatment periods than conventional treatment (Figures 19a,b,c). Furthermore, an 
increase in the number o f sub-Gi or apoptotic cells was seen following prolonged 
incubation (5-7 days) with liposomal taxol when compared to conventional taxol 
treatment. Similar effects were seen in three MCF-7 cell lines (Tables 6 a,b,c). Results 
from these studies have also shown that mitotic arrest is an early effect o f taxol in the 
cells, and it is ultimately indicative o f  imminent cell death (Moos and Fitzpatrick, 1998). 
This process is accelerated by liposomal delivery o f the drug. Determination o f  mitotic 
indexes was utilized to compare the amount o f  mitotic arrest induced by the two taxol 
formulations, and to confirm results o f flow cytometry data. In all three MCF-7 cell lines 
examined, the pereentage o f mitotic arrest was lower than the percentage o f G2 /M arrest 
as determined by flow cytometry. Mitotic indexes correlated with flow cytometry data in 
all cases. These results can be used to distinguish between the population o f cells in G2
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versus the population o f cells in mitotic arrest that are destined for apoptosis as 
determined by flow cytometry.
Degraded or sub-Gi DNA was used as an indicator o f  apoptosis in flow  
cytometry studies (Huang et al., 1995). DNA fragmentation assays following liposomal 
or conventional taxol treatment were carried out on the three MCF-7 cell lines as another 
measure o f  apoptosis, and to confirm results obtained through flow cytometrie analysis o f  
the cell cycle. Results o f  the DNA fragmentation assay were reflective o f  the number o f  
floating cells, as these were the cells isolated for analysis. The inherent number o f  
floating or dead cells in normal, untreated culture conditions varied between the three 
strains o f MCF-7 cells, which can partially be accounted for by cell doubling times. As a 
result, the values for total DNA fragmentation must also take into aecount the cell 
doubling time and individual growth characteristics o f the culture. DNA fragmentation 
was significantly increased in a taxol-resistant clone cell line, which also had the shortest 
doubling time, and therefore, the highest number o f cells at the end-point o f  the assay. 
Results for wild-type and tax-resistant MCF-7 cells were not as prominent, likely due to 
their slower growth rates and lower number o f floating cells (Figure 21a,b).
To compare the uptake o f  the two taxol formulations and to correlate 
intracellular drug concentrations with effectiveness o f treatment, UPLC analysis was 
carried out on three MCF-7 cell lines. Taxol levels from cell lysates exposed to liposomal 
taxol were higher than those observed following exposure to eonventional taxol. 
Furthermore, the levels o f taxol in the media isolated from cell cultures challenged with 
liposomal taxol or conventional taxol were lower in those cell cultures challenged with 
liposomal taxol (Figure 22, Table 8 ). These data suggest that cells with the greatest
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uptake o f taxol had the lowest concentrations o f  the drug remaining in the media. These 
findings also eorrelate with results o f mitotic arrest and eell killing, suggesting that 
increased uptake is responsible for the increased effects on these cells.
The taxol-resistant MCF-7 eells were further characterized to elueidate the 
mechanism o f resistance. With regards to growth rates, the tax-resistant MCF-7 eells 
were shown to have a significantly slower growth rate than the parental eells from which 
they were derived. Similar results were also reported by Li et al., 2004, as drug-resistant 
ovarian carcinoma cell lines were shown to have longer doubling times than their 
parental derivatives. Slower growth rates would allow the cells to decrease their 
metabolism, thereby decreasing their uptake o f  the drug, and possibly evading cell death. 
However, the taxol-resistant elone had a shorter doubling time than the wild-type cells. 
This suggests that an alternate mechanism o f resistance is functioning in these cells, as 
they are not evading death by simply slowing their uptake o f the drug.
Western blot analysis was used to determine if  taxol-resistant MCF-7 cells 
overexpressed the P-glycoprotein, coded by the resistance gene M D R l, as this is one of 
the most commonly-reported mechanisms o f resistance (Gottesman et al., 2002; 
Nakagawa et al., 1992; Trock et al., 1997). It was determined that one o f  the two 
resistant cell lines (tax-resistant) over-expressed the P-gp membrane pump, whieh 
correlates with results found by the group that initially donated the cell line (Guo et al., 
2004). This particular cell line also had a slower doubling time, suggesting that a 
combination o f  slow uptake and drug efflux are responsible for the resistanee phenotype. 
Overall, this study demonstrated the ability o f  liposomal-eneapsulation o f taxol to 
partially bypass efflux from the cell by this protein membrane pump.
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The taxol-resistant MCF-7 clone did not over-express the P-gp membrane 
pump, suggesting that an alternate mechanism is responsible for the resistance in these 
cells. Results from this study indieate that this clone is only highly resistant to taxol at 
high concentrations o f the drug (>1 pM), suggesting a possible mechanism o f resistance 
that is induced by taxol treatment. Further study would be needed to precisely elucidate 
the mechanism o f resistance displayed by these cells.
In order to validate the usefulness o f liposomal taxol in the treatment o f  cancer, 
the effects o f  liposomal taxol and conventional taxol were compared on another eancer 
eell type, A549 lung caneer cells, as lung cancer is commonly treated with taxol (Monzo 
et al., 1999; Rosell et al., 2003; Seve et al., 2005; Shi et al., 2007; Yeh et al., 2003). 
These cells are sensitive to taxol treatment, and have a sequence o f  cell killing similar to 
that o f MCF-7 cells that takes place upon treatment with the drug. Upon taxol treatment, 
these cells enter mitotic arrest at early time-points, followed by cell death and DNA  
degradation. Preliminary results presented here (Figure 27, Tables 10, 11) indicate that 
liposomal encapsulation o f  taxol provides a slight advantage in delivery o f the drug in 
comparison to the conventional formulation. However, the differenee between the two 
formulations is not as significant as that observed in the MCF-7 breast caneer cells.
This anomaly ean be explained by the inherent differenees between the two eell 
lines, which may be the result o f the expression o f different genes and proteins within the 
cells. It has been shown that significantly altered gene expression in caneer cells 
compared to normal tissue was largely tissue speeific (Richardson et al., 2005; 
Villeneuve et al., 2006). As a result, liposomal encapsulation o f taxol may improve 
delivery in one cell line, but not in another. Studies on alternate lung and breast eaneer
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cell lines may demonstrate different effects upon treatment with any formulation o f  taxol, 
depending on the individual characteristics o f  the cells.
Overall, results from flow cytometric analysis o f the cell cycle, UPLC 
determination o f cellular uptake o f  taxol, DNA fragmentation gels, and determination o f  
mitotic indexes, conclude that liposomal eneapsulation o f taxol improves delivery and 
cytotoxic effects o f the drug, in breast cancer cells cultured in vitro, at least partially 
overcoming the resistance mechanisms in these cells. The characteristics o f  this 
liposomal formulation, as conferred by its stability, high encapsulation efficiency, small 
particle diameter, and ability to deliver high levels o f  taxol within eells, might be o f  use 
in the treatment o f breast cancer. Further studies in experimental animals are warranted 
in order to characterize the effectiveness o f  this formulation in vivo.
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VIII. Future Directions
Based on the results o f this projeet, further study o f  this new formulation o f  
liposomal taxol is warranted. Future experiments should focus on the effects o f  
liposomal taxol on different cell types that would commonly be treated with the drug, 
such as ovarian cancer, and different types o f breast and lung cancer cells. In addition, 
liposomal taxol must be tested to determine its safety, pharmaeokinetics and 
pharmacodynamics in vivo. If these studies were to be suceessful and determine that 
this new formulation o f liposomal taxol is safe and effeetive for use on human patients, 
phase I clinieal trials would then need to be performed on a small number o f  human 
patients. Prior to the commercial use o f this drug, it would also need to pass through 
phase II and phase III clinieal trials. However, because taxol is already widely used, and 
the liposomes are made o f naturally-occurring, non-immunogenic lipids, it seems highly 
likely that there would be few novel side effects or toxicities associated with this new  
formulation. In fact, this new formulation should alleviate many o f  the side effects 
associated with the Cremophor EL (CrEL) vehicle that is currently used to deliver taxol.
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IX. Conclusion
The results o f  this in vitro study have demonstrated that liposomal encapsulation 
o f taxol can improve delivery o f the drug over the conventional formulation. This new  
liposomal formulation, composed o f the non-toxic, naturally-occurring lipids DMPG and 
DPPC, is able to cause increased mitotie arrest, DNA degredation, and cell death at 
earlier time-points in MCF-7 breast cancer cells than its conventional counterpart. 
Improved cell killing was correlated to increase uptake o f the drug. Liposomal 
encapsulation o f taxol also allowed the drug to partially overcome resistance mechanisms 
in two separate taxol-resistant MCF-7 cell lines. These results suggest that future studies 
on this new formulation are warranted. Speeifically, it should be tested in vivo to 
complete pre-clinical trials.
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List of Abbreviations
A B1-007 -  Abraxane
ABC -  ATP-binding cassette
ATCC -  American Tissue Culture Collection
ATP -  adenosine triphosphate
Bcl-2 -  B-cell leukemia 2
BMS -  Bristol Myers Squibb
BRCAl -  Breast cancer gene 1
BrDU -  bromodeoxyuracil
CrEL (Cremophor EL) -  polyethoxylated castor oil
DAB -  10-deacetylbaccatin III
DAPI - 4 ’,6-diamindino-2 phenylindole
DFS -  Disease-free survival
DMEM -  Dulbeeeo’s Modified Eagle’s Medium
DMPC - Dimyristoyl-phosphadtidylcholine
DMPG - dimyristoyl phosphatidylglycerol
DMSG -  dimethyl sulfoxide
DPPC - dimyristoyl phosphatidyleholine
DSPC - Disaturated-phosphatidylcholine
ECM -  extracellular matrix
EGFR -  epidermal growth factor receptor
EPR effect -  enhanced permeability and retention effect
FACS -  fluorescence automated cell sorter
FBS -  fetal bovine serum
FDA -  Food and Drug Administration
G 1 -  gap 1  phase
G2 -  gap 2 phase
HPLC -  high performanee liquid chromatography 
HSF-55 -  Human dermal fibroblast cells 
IgM - immunoglobulins 
M DRl -  multidrug resistance 1
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M-phase -  mitosis
MTl-MMP -  membrane type 1 matix metalloproteinase
MTT - 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolinm bromide
NB -  nuclei buffer
NCI -  National Cancer Institute
ND -  not determined
OS -  overall survival
PBS -  phosphate buffered saline
PCS -  photon correlation speetroscopy
PEG -  polyethylene glycol
P-gp -  P-glycoprotein
PI-3 -  phosphatidylinositol 3 ’ kinase
PMP22 -  peripheral myelin protein 22
RECIST -  Response Evaluation Criteria in Solid Tumours
S -  synthesis phase
SDS -PAGE- sodium dodeeyl sulphate polyacrylamide gel eletrophoresis
siRNAs -  small interfering RNAs
Taxol -  paclitaxel
t-BME -  tert-butylmethyl ether
UPLC -  ultra-performanee liquid chromatography
UV -  ultraviolet
WHO -  World Health Organization
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Appendix A: Buffers and Solutions
Phosphate Buffered Saline (PBS) (lOX) 
7.4 (IL)
80g NaCl 
2gK C l
2g KH2 PO4 .2 H2 O 
Fill up to IL with DDW
Nuclei buffer (NB) 100ml:
8 .6 g sucrose (0.25M)
1.16gNaCl (0.2M)
1ml IM Tris-HCl pH 8.0 (lOmM)
0.2ml IM MgC12 (2mM)
0.1ml IM CaC12 (ImM)
4ml 25% TntonX-100 (1%)
Fill up to lOOmL with DDW. Sterilize in
autoclave
Store at 4°C
Propidium Iodide (PI) (50ml)
50ml IX PBS
50ug/ml RNAse
50uL o f 5mg/ml stock PI
Makes 5ug/ml solution
Keep at 4°C and protected from light
10% APS
0.1 g Ammonium persulfate 
1 ml water
lOX Running Buffer (IL) 
144g Glyeine 
30.3g Tris Base 
50ml 10% SDS
MTT (5mg/ml) (40ml)
0.2g MTT 
40ml DDW  
Syringe Filter
Store at 4°C and protected from light
Mounting Medium (1ml)
Img p-phenylenediamine (anti-fade) 
lOOuL I X  PBS 
900uL glycerol
Store at 4°C and proteeted from light 
IX Running Buffer (IL)
900ml water
100ml I OX running buffer
lOX Transfer buffer (IL) 
144g Glycine 
30.3g Tris base
IX Transfer Buffer (IL) 
700ml water 
2 0 0 ml methanol 
100ml 1 OX transfer buffer
1 OX TBS
30.3g Tris Base
87.6g Sodium Chloride
IX  TBST 
900ml water 
100ml lOX TBS 
1ml Tween 20
Developing Solution #1 
17.7ml Water 
2ml IM Tris HCl (pH 8.5) 
8 8 uL p-Coumaric Acid
Developing Solution #2 
18ml Water
2ml IM Tris HCl (pH 8.5) 
12uL Hydrogen Peroxide
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200uL Luminol
Luminol (lOmL) 
0.44g Luminol 
10ml DMSO
p-Coumaric Acid (10ml) 
0.15g p-Coumaric Acid 
10ml DMSO
10% SDS-Polyacrylamide Gel (lOmL)
2.5mL 40% Acrylamide
2.5mL 1.5M Tris-HCl (pH 8 .8 )
lOOuL 10% SDS
4.85mL Water
5uL TEMED
50uL 10% APS
Stacking Gel (5mL)
0.5ml 40% Acrylamide 
1.26mL 1.5M Tris-HCl (pH 6 .8 ) 
50uL 10% SDS 
3.18mL Water
1.3% agarose gel (30ml) 
0.4g Seakem agarose 
30ml 1 X TBE
Freezing medium 
50% FBS 
43% medium 
7% DMSO 
IX TBE
100ml lOX TBE 
900ml DDW
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